Interventions for sexual dysfunction following stroke (Review)

Stratton H, Sansom J, Brown-Major A, Anderson P, Ng L

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEADER</td>
<td>1</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>1</td>
</tr>
<tr>
<td>PLAIN LANGUAGE SUMMARY</td>
<td>2</td>
</tr>
<tr>
<td>SUMMARY OF FINDINGS</td>
<td>4</td>
</tr>
<tr>
<td>BACKGROUND</td>
<td>10</td>
</tr>
<tr>
<td>OBJECTIVES</td>
<td>11</td>
</tr>
<tr>
<td>METHODS</td>
<td>11</td>
</tr>
<tr>
<td>RESULTS</td>
<td>14</td>
</tr>
<tr>
<td>Figure 1</td>
<td>15</td>
</tr>
<tr>
<td>Figure 2</td>
<td>17</td>
</tr>
<tr>
<td>DISCUSSION</td>
<td>20</td>
</tr>
<tr>
<td>AUTHORS’ CONCLUSIONS</td>
<td>22</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td>22</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>23</td>
</tr>
<tr>
<td>CHARACTERISTICS OF STUDIES</td>
<td>25</td>
</tr>
<tr>
<td>DATA AND ANALYSES</td>
<td>31</td>
</tr>
<tr>
<td>Analysis 1.1. Comparison 1: Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention, Outcome 1: Sexual function - intravaginal ejaculatory latent time</td>
<td>31</td>
</tr>
<tr>
<td>Analysis 1.2. Comparison 1: Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention, Outcome 2: Sexual function - non-validated measure</td>
<td>31</td>
</tr>
<tr>
<td>Analysis 1.3. Comparison 1: Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention, Outcome 3: Partner sexual satisfaction - non-validated measure</td>
<td>32</td>
</tr>
<tr>
<td>Analysis 1.4. Comparison 1: Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention, Outcome 4: Adverse effects</td>
<td>32</td>
</tr>
<tr>
<td>APPENDICES</td>
<td>32</td>
</tr>
<tr>
<td>HISTORY</td>
<td>39</td>
</tr>
<tr>
<td>CONTRIBUTIONS OF AUTHORS</td>
<td>39</td>
</tr>
<tr>
<td>DECLARATIONS OF INTEREST</td>
<td>39</td>
</tr>
<tr>
<td>SOURCES OF SUPPORT</td>
<td>39</td>
</tr>
<tr>
<td>DIFFERENCES BETWEEN PROTOCOL AND REVIEW</td>
<td>39</td>
</tr>
</tbody>
</table>
Interventions for sexual dysfunction following stroke

Hezekiah Stratton1, Joshua Sansom1, Anita Brown-Major2,3, Paul Anderson1,4,5, Louisa Ng1,6,7

1Department of Medicine, University of Melbourne, Melbourne, Australia. 2Thrive Rehab, Melbourne, Australia. 3Allied Health Department (Occupational Therapy Services), The Royal Melbourne Hospital, Melbourne, Australia. 4Department of Urology, The Royal Melbourne Hospital, Melbourne, Australia. 5Epworth Healthcare, Melbourne, Australia. 6Department of Rehabilitation Medicine, The Royal Melbourne Hospital, Melbourne, Australia. 7Epworth Monash Rehabilitation Medicine, Melbourne, Australia

Contact address: Louisa Ng, louisa.ng@mh.org.au.

Editorial group: Cochrane Stroke Group.


Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background
Sexual dysfunction following stroke is common but often is poorly managed. As awareness of sexual dysfunction following stroke increases as an important issue, a clearer evidence base for interventions for sexual dysfunction is needed to optimise management.

Objectives
To evaluate the effectiveness of interventions to reduce sexual dysfunction following stroke, and to assess adverse events associated with interventions for sexual dysfunction following stroke.

Search methods
We conducted the search on 27 November 2019. We searched the Cochrane Central Register of Controlled Trials (CENTRAL; from June 2014), in the Cochrane Library; MEDLINE (from 1950); Embase (from 1980); the Cumulative Index to Nursing and Allied Health Literature (CINAHL; from 1982); the Allied and Complementary Medicine Database (AMED; from 1985); PsycINFO (from 1806); the Physiotherapy Evidence Database (PEDro; from 1999); and 10 additional bibliographic databases and ongoing trial registers.

Selection criteria
We included randomised controlled trials (RCTs) that compared pharmacological treatments, mechanical devices, or complementary medicine interventions versus placebo. We also included other non-pharmacological interventions (such as education or therapy), which were compared against usual care or different forms of intervention (such as different intensities) for treating sexual dysfunction in stroke survivors.

Data collection and analysis
Two review authors independently selected eligible studies, extracted data, and assessed study quality. We determined the risk of bias for each study and performed a ‘best evidence’ synthesis using the GRADE approach.

Main results
We identified three RCTs with a total of 212 participants. We noted significant heterogeneity in interventions (one pharmacological, one physiotherapy-based, and one psycho-educational), and all RCTs were small and of ‘low’ or ‘very low’ quality. Based on these RCTs, data are insufficient to provide any reliable indication of benefit or risk to guide clinical practice in terms of the use of sertraline, specific pelvic floor muscle training, or individualised sexual rehabilitation.
Authors' conclusions

Use of sertraline to treat premature ejaculation needs to be tested in further RCTs. The lack of benefit with structured sexual rehabilitation and pelvic floor physiotherapy should not be interpreted as proof of ineffectiveness. Well-designed, randomised, double-blinded, placebo-controlled trials of long-term duration are needed to determine the effectiveness of various types of interventions for sexual dysfunction. It should be noted, however, that it may not be possible to double-blind trials of complex interventions.

Plain Language Summary

Treatments for sexual problems following stroke

Background

One of the most common but least talked about effects of stroke is sexual dysfunction, with 50% or more of stroke survivors experiencing a degree of sexual decline post stroke. This is not always well recognised, and it is often poorly managed. Management options are very broad and can include medications, counselling, and physical therapy.

Review question

We wanted to find out whether some treatments are better or worse than alternatives.

Search date

The evidence is current to 27 November 2019.

Study characteristics

Population: we included studies in which participants were adults who had had a stroke.

Intervention: interventions included medications or other treatments, such as rehabilitation, used to manage sexual problems following stroke.

Comparison: we compared interventions such as medications against ‘fake’ medications, which do not contain active substances that affect sexual function. We compared interventions such as rehabilitation, education, or therapy to usual care or alternative treatment.

Outcome: we divided outcomes into primary and secondary outcomes. Primary outcomes focused on sexual function or sexual satisfaction in stroke survivors and their partners. Secondary outcomes focused on quality of life, psychological well-being (anxiety, depression, stress), satisfaction with intervention, sexual knowledge, and marital/relationship satisfaction (including partner satisfaction) in stroke survivors and their partners. We also reported adverse events.

Time/duration: we included studies of all durations: short (≤ 6 months), medium (between 6 and 18 months), and long (≥ 18 months).

Key results

We found three trials designed to reduce sexual dysfunction after stroke. One trial compared a medication called sertraline to methylcobalamin (vitamin B12) to help with premature ejaculation. A second trial compared a structured rehabilitation programme (which had face-to-face counselling and written education) to written education alone and found no clear difference in terms of sexual function, mood, stress, or quality of life. A third trial compared pelvic floor training (exercises to strengthen pelvic floor muscles) to standard rehabilitation and found no clear differences in terms of erection and quality of life. We were uncertain of the results because all three trials were small and of low or very low quality. Also, each trial compared different treatments, which meant that results could not be combined.

Side effects (mostly nausea or diarrhoea) were reported for sertraline (20 of 58 participants). No harmful events were reported with pelvic floor training, and no information was provided on harmful events related to sexual rehabilitation.

Study funding sources

The study that compared the medication (sertraline) to vitamin B12 did not describe any funding sources. The study that compared pelvic floor training to standard rehabilitation was funded through grants from the Association of Danish Physiotherapists Research Foundation, the Association of Danish Physiotherapists Practise Foundation, the Foundation of 12.12.1981, Lykkefeldts Grant, the Foundation of Lundbeck (UCSF), and the Department of Physiotherapy and Occupational Therapy Glostrup Hospital, University of Copenhagen. The study that compared a structured rehabilitation programme to written education alone was funded by the Victor Hurley Medical Research Grant-in-Aid and by the AFRM Ipsen Open Research Fellowship.

Quality of evidence
We are uncertain of the results because all three studies were small and of poor quality. Also, each of the three studies compared different treatments, which meant that we could not combine study results.

**Conclusion**

All three treatments (sertraline, structured sexual rehabilitation, and pelvic floor physiotherapy) need to be tested in further studies. Further research is needed to assess the effectiveness of treatments for sexual problems after stroke.
# SUMMARY OF FINDINGS

Summary of findings 1. Pharmacological interventions compared with placebo/usual care or different forms of intervention

**Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke**

**Patient or population:** men (aged between 23 and 45) with premature ejaculation within 3 months after stroke

**Settings:** unclear (likely inpatient, continued into outpatient)

**Intervention:** sertraline

**Comparison:** methylcobalamin

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks*</th>
<th>No. of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sexual function (primary outcome)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measure 1: mean intravaginal ejaculatory latent time at 4 weeks</td>
<td>Placebo (Methylcobalamin)</td>
<td>2.1 (SD 0.4)</td>
<td>0.8 higher (SD 0.5)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td></td>
<td>Sertraline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measure 1: mean intravaginal ejaculatory latent time at 8 weeks (end of intervention)</td>
<td></td>
<td>3.8 (SD 0.5)</td>
<td>2 higher (SD 0.7)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measure 1: mean intravaginal ejaculatory latent time at 12 weeks</td>
<td></td>
<td>4.5 (SD 0.7)</td>
<td>1.6 higher (SD 0.9)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measure 2: mean non-validated measure for “sexual functioning” ** at 4 weeks</td>
<td></td>
<td>4.4 (SD 2.1)</td>
<td>1.5 higher (SD 1.9)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measure 2: mean non-validated measure for “sexual functioning” ** at 8 weeks (end of intervention)</td>
<td></td>
<td>5.3 (SD 1.9)</td>
<td>1.9 higher (SD 2.2)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measure 2: mean non-validated measure for “sexual functioning” ** at 12 weeks</td>
<td></td>
<td>6.5 (SD 2.7)</td>
<td>1.8 higher (SD 2.2)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sexual satisfaction (primary outcome)</strong></td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Not addressed
### Quality of life (secondary outcome)

Not addressed

<table>
<thead>
<tr>
<th>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 4 weeks</th>
<th>8.9 (SD 1.5)</th>
<th>1.2 higher (SD 1.4)</th>
<th>114 (1 study)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 8 weeks (end of intervention)</td>
<td>10.8 (SD 1.7)</td>
<td>2.5 higher (SD 1.6)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 12 weeks</td>
<td>10.8 (SD 1.7)</td>
<td>2.7 higher (SD 1.7)</td>
<td>114 (1 study)</td>
</tr>
</tbody>
</table>

### Psychological well-being (secondary outcome)

Not addressed

<table>
<thead>
<tr>
<th>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 4 weeks</th>
<th>8.9 (SD 1.5)</th>
<th>1.2 higher (SD 1.4)</th>
<th>114 (1 study)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 8 weeks (end of intervention)</td>
<td>10.8 (SD 1.7)</td>
<td>2.5 higher (SD 1.6)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 12 weeks</td>
<td>10.8 (SD 1.7)</td>
<td>2.7 higher (SD 1.7)</td>
<td>114 (1 study)</td>
</tr>
</tbody>
</table>

### Satisfaction with intervention (secondary outcome)

Not addressed

<table>
<thead>
<tr>
<th>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 4 weeks</th>
<th>8.9 (SD 1.5)</th>
<th>1.2 higher (SD 1.4)</th>
<th>114 (1 study)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 8 weeks (end of intervention)</td>
<td>10.8 (SD 1.7)</td>
<td>2.5 higher (SD 1.6)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 12 weeks</td>
<td>10.8 (SD 1.7)</td>
<td>2.7 higher (SD 1.7)</td>
<td>114 (1 study)</td>
</tr>
</tbody>
</table>

### Marital/relationship/partner satisfaction (secondary outcome)

<table>
<thead>
<tr>
<th>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 4 weeks</th>
<th>8.9 (SD 1.5)</th>
<th>1.2 higher (SD 1.4)</th>
<th>114 (1 study)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 8 weeks (end of intervention)</td>
<td>10.8 (SD 1.7)</td>
<td>2.5 higher (SD 1.6)</td>
<td>114 (1 study)</td>
</tr>
<tr>
<td>Outcome measure: mean non-validated measure for &quot;partner sexual satisfaction&quot;** at 12 weeks</td>
<td>10.8 (SD 1.7)</td>
<td>2.7 higher (SD 1.7)</td>
<td>114 (1 study)</td>
</tr>
</tbody>
</table>

### Adverse effects (secondary outcome)

Outcome measure: adverse effects***

| Outcome measure: adverse effects*** | OR 0.48 | OR 1.6 higher | 114 (1 study) |

*The assumed risk is based on the outcome mean of the control group. The corresponding risk is based on the outcome mean of the comparison group. The relative effect of the intervention is denoted in brackets (lower/higher/no difference).

**No further description of the scale has been provided by the authors of the study.

***Adverse effects were mild and most commonly were gastrointestinal.

N/A: not applicable; OR: odds ratio; SD: standard deviation.

**Based on GRADE criteria, the quality of evidence has been triple-downgraded to "very low". First, a single randomised controlled trial is contributing to the overall quality of evidence. Second, there are significant limitations in the design and implementation of the included study (high or unclear risk of bias in all risk of bias criteria) for which we have downgraded the evidence by a further two levels. There is also a likelihood of publication bias; however, the quality of evidence is already at the lowest possible level.
## Summary of findings 2. Non-pharmacological interventions compared with placebo/usual care or different forms of intervention

### Intervention 1. Sexual rehabilitation programme compared with written education alone for sexual dysfunction after stroke

**Patient or population:** people within 3 months after stroke  
**Settings:** inpatient  
**Intervention:** individualised structured sexual rehabilitation  
**Comparison:** written educational materials

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks*</th>
<th>No. of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sexual function (primary outcome)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Written educational materials alone</td>
<td></td>
<td>2 lower (IQR 16.8 to 39) (no significant difference)</td>
<td>68 (1 study)</td>
<td>low</td>
</tr>
<tr>
<td>Sexual rehabilitation programme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measure: Median Sexual Functioning Questionnaire Short Form at 6 weeks</td>
<td>28 (IQR 16 to 40)</td>
<td>68 (1 study)</td>
<td>low</td>
<td></td>
</tr>
<tr>
<td>Outcome measure: Median Sexual Functioning Questionnaire Short Form at 6 months</td>
<td>35 (IQR 18.5 to 41)</td>
<td>68 (1 study)</td>
<td>low</td>
<td></td>
</tr>
<tr>
<td>Sexual satisfaction (primary outcome)</td>
<td></td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Not addressed</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality of life (secondary outcome)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Written educational materials alone</td>
<td></td>
<td>0.4 lower (IQR 3.5 to 4.7) (no significant difference)</td>
<td>68 (1 study)</td>
<td>low</td>
</tr>
<tr>
<td>Sexual rehabilitation programme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Outcome measure: Median Stroke and Aphasia Quality of Life Scale-39 Generic at 6 weeks</td>
<td>4.5 (IQR 3.7 to 4.7)</td>
<td>68 (1 study)</td>
<td>low</td>
<td></td>
</tr>
<tr>
<td>Outcome measure: Median Stroke and Aphasia Quality of Life Scale-39 Generic at 6 months</td>
<td>4.4 (IQR 3.7 to 5)</td>
<td>68 (1 study)</td>
<td>low</td>
<td></td>
</tr>
</tbody>
</table>
### Psychological wellbeing (secondary outcome)

<table>
<thead>
<tr>
<th>Outcome measure: Median Depression, Anxiety, and Stress Scale at 6 weeks</th>
<th>Depression 2 (IQR 0 to 9), Anxiety 2 (IQR 0 to 6), Stress 0 (IQR 0 to 10)</th>
<th>Depression 2 higher (IQR 0 to 14) (no significant difference)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Anxiety 3 higher (IQR 0 to 9) (no significant difference)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stress 5 higher (IQR 0 to 12.5) (no significant difference)</td>
</tr>
<tr>
<td>Outcome measure: Median Depression, Anxiety, and Stress Scale at 6 months</td>
<td>Depression 2 (IQR 0 to 10), Anxiety 2 (IQR 0 to 5), Stress 4 (IQR 0 to 11)</td>
<td>Depression 2 higher (IQR 0 to 14) (no significant difference)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anxiety 2 lower (IQR 0 to 9) (no significant difference)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stress 2 higher (IQR 0 to 15) (no significant difference)</td>
</tr>
</tbody>
</table>

68 (1 study)  low

<table>
<thead>
<tr>
<th>Satisfaction with intervention (secondary outcome)</th>
<th>Not addressed</th>
</tr>
</thead>
</table>

| Marital/relationship/partner satisfaction (secondary outcome) | Not addressed |

<table>
<thead>
<tr>
<th>Adverse effects (secondary outcome)</th>
<th>No data provided</th>
</tr>
</thead>
</table>

### Intervention 2: Pelvic floor muscle training compared with standard rehabilitation for erectile dysfunction after stroke

**Patient or population:** men with lower urinary tract symptoms and erectile dysfunction more than 1 month following stroke

**Settings:** outpatient

**Intervention:** pelvic floor muscle training

**Comparison:** standard general rehabilitation without specific treatment for lower urinary tract symptoms

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks*</th>
<th>No. of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Standard general rehabilitation</td>
<td>Pelvic floor muscle training</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------</td>
<td>-------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sexual function</strong> (primary outcome)</td>
<td>Outcome measure: Median International Index of Erectile Function Questionnaire at 3 months (end of intervention)</td>
<td>18 (IQR 5 to 25)</td>
<td>2 higher (IQR 5 to 25) (no significant difference)</td>
<td>31 (1 study)</td>
</tr>
<tr>
<td></td>
<td>Outcome measure: Median International Index of Erectile Function Questionnaire at 6 months</td>
<td>11 (IQR 5 to 18)</td>
<td>4 higher (IQR 5 to 25) (no significant difference)</td>
<td>31 (1 study)</td>
</tr>
<tr>
<td><strong>Sexual satisfaction</strong> (primary outcome)</td>
<td>Not addressed</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Quality of life</strong> (secondary outcome)</td>
<td>Outcome measure: median non-validated &quot;erectile dysfunction-induced bother&quot; questionnaire** at 3 months (end of intervention)</td>
<td>3 (IQR 2 to 5)</td>
<td>1 higher (IQR 3 to 4) (no significant difference)</td>
<td>31 (1 study)</td>
</tr>
<tr>
<td></td>
<td>Outcome measure: median non-validated &quot;erectile dysfunction-induced bother&quot; questionnaire** at 6 months</td>
<td>3 (IQR 2 to 5)</td>
<td>1 lower (IQR 2 to 4) (no significant difference)</td>
<td>31 (1 study)</td>
</tr>
<tr>
<td><strong>Psychological well-being</strong> (secondary outcome)</td>
<td>Not addressed</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Satisfaction with intervention</strong> (secondary outcome)</td>
<td>Not addressed</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td><strong>Marital/relationship/partner satisfaction</strong> (secondary outcome)</td>
<td>Not addressed</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>
No addressed

<table>
<thead>
<tr>
<th>Adverse effects (secondary outcome)</th>
<th>None reported</th>
<th>None reported</th>
<th>31 (1 study)</th>
<th>⊗⊝⊝⊝ very low</th>
</tr>
</thead>
</table>

Outcome measure: adverse effects

*The assumed risk* is based on the outcome median of the control group. The corresponding risk is based on the outcome median of the comparison group. The relative effect of the intervention is denoted in brackets (lower/higher/no difference).

**“If you were to spend the rest of your life with your ED problems as they are now, how would you feel about that?”**

IQR: interquartile range; N/A: not applicable.

GRADE Working Group grades of evidence.

**High quality:** further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** we are very uncertain about the estimate.

We have not been able to combine the results of these two interventions given the heterogeneity of the interventions themselves.

\(^{a}\)With regards to the non-pharmacological intervention of a sexual rehabilitation programme compared with written education alone, based on GRADE criteria, the quality of the evidence has been double-downgraded to 'low'. First, a single randomised controlled trial is contributing to the overall quality of evidence. Second, there are some limitations in the design and implementation of the included study, specifically, participants and personnel were not blinded. It is recognised however that such blinding would be challenging to institute given the nature of the study. In recognition of the possible risk of bias introduced by the lack of such blinding, we have downgraded the evidence by a further level.

\(^{b}\)With regards to the non-pharmacological intervention of pelvic floor muscle training compared with standard rehabilitation for erectile dysfunction, based on GRADE criteria, the quality of evidence has been triple-downgraded to 'very low'. First, a single randomised controlled trial is contributing to the overall quality of evidence. Second, there are significant limitations in the design and implementation of the included study (three criteria judged as introducing high risk of bias) for which we have downgraded the evidence by a further two levels.

**Summary of findings 3. Complementary medicine interventions compared with placebo/usual care or different forms of intervention**

No included studies
BACKGROUND

Stroke is a leading cause of mortality and disability (ABS 2017). It is estimated that one in six people worldwide will experience a stroke in their lifetime – in 2018, 56,000 new strokes or recurrent strokes occurred in Australia (NSF 2018), and 795,000 in the USA (CDC 2017). In the same year, over 475,000 people in Australia and over 7,000,000 people in the USA were living with the effects of stroke (CDC 2017; NSF 2018). The burden of disease and the economic impact of stroke upon stroke survivors, their caregivers (often family members), and society are substantial, with annual national costs of AUD 5 billion in Australia (NSF 2018), along with lifetime costs per patient ranging from USD 11,787 to USD 3,3035,671 in the USA (Palmer 2005).

Description of the condition

One of the most common but least talked about effects of stroke is sexual dysfunction, with 50% or more of stroke survivors experiencing a degree of sexual decline post stroke (Giaquinto 2003; Korpelainen 1999; Schmitz 2010; Stein 2013; Tamam 2008). Sexual dysfunction is often multi-factorial in origin, and contributing causes can be divided broadly into the following categories.

- Primary issues with sexual dysfunction as a direct result of the stroke. Examples may include decline in libido and coital frequency, decline in vaginal lubrication, or orgasm and erection and ejaculation issues (Giaquinto 2003; Monga 1986; Tamam 2008).
- Related medical issues, such as medications and pre-morbidity medical conditions (diabetes, hypertension, cardiac issues), may also contribute to these effects (Giaquinto 2003; Sjogren 1981).
- Secondary causes of sexual dysfunction, whereby the stroke results in sensorimotor problems, such as hemiplegia or spasticity, pain, or bowel or bladder dysfunction, which in turn can affect sexual function due to issues such as loss of ability to position oneself during sexual activity.
- Tertiary causes such as psychological adjustment issues, cognitive or behavioural issues, or both.
- Psychological adjustment issues may include body image changes, loss of self-esteem, anxiety, stress, depression, fear of new stroke, and marital conflict (change in roles, fear that able-bodied partner will leave, difficulties stemming from the spouse having a dual role of lover as well as carer) (Giaquinto 2003; Korpelainen 1999).
- Cognitive or behavioural issues, or both, may include poor judgement, egocentricity, emotional liability, disinhibition, low tolerance for delayed gratification, and poor memory.
- Issues may relate not only to stroke survivors but also to their spouses, with up to 88% stating they would not like to have sexual activity with a ‘sick person’ (Giaquinto 2003).

Interventions for sexual dysfunction following stroke (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Sexuality is a broad concept, and it may be experienced and expressed in a variety of ways, including thoughts, fantasies, desires, beliefs, attitudes, values, behaviours, practices, roles, and relationships (WHO 2006). It is closely linked with personal identity and gender. It should be noted that studies of stroke interventions typically report the gender of participants in binary terms (male or female, men or women), and that there is generally an assumption that participants are cis-gendered (sense of personal identity and gender corresponds with their birth sex). However, this is potentially neither accurate nor inclusive. For this review, we have chosen to use the phrase ‘regardless of gender’ whenever possible to include people regardless of their gender identity. Similarly, ‘their’ is used rather than ‘his or her’. We use binary terms when necessary, such as when reporting information from studies.

Description of the intervention

Types of interventions for sexual dysfunction include:

- Pharmacological interventions, such as phosphodiesterase-5 inhibitors, intracavernosal injections, intraurethral suppositories, and hormonal therapy (Vecchio 2010);
- Non-pharmacological interventions, including:
  - mechanical devices (such as vacuum pumps, penile implants, penile prostheses, and lubricating gels);
  - psycho-educational interventions (such as counselling and psychotherapy); and
  - physical therapy (such as physiotherapy for bed mobility) (Miles 2007); and
- Complementary medicine interventions, such as gingko biloba and ginseng (Miles 2007).

Interventions are not mutually exclusive and may be used in combination. An example of a comprehensive intervention for sexual dysfunction following stroke is sexual rehabilitation. Rehabilitation is defined as "a problem-solving educational process aimed at reducing disability and handicap (participation) experienced by someone as a result of disease or injury" (Wade 1992). The specific aims of stroke sexual rehabilitation are to assess existing sexual issues, provide information on concerns, and support safe return to sexual activity after a stroke (Byrne 2016). Sexual rehabilitation is tailored according to individual needs and is delivered in a co-ordinated manner by medical staff, together with representatives of one or more disciplines (physiotherapy, occupational therapy, social work, psychology, nursing). Sexual rehabilitation is designed to be person-centred, time-based, and functionally oriented and aims to maximise activity and participation (social integration) via a biopsychosocial model. Counselling may form a large (and potentially the only) component of sexual rehabilitation and may address sexual performance concerns, issues related to medication and comorbid conditions that may affect sexual function, and specific psychological or interpersonal factors (Lue 2004). Counselling may be delivered in a one-on-one or group setting. In addition to counselling, sexual rehabilitation may involve other aspects of physical rehabilitation, such as mobility training by the physiotherapist to optimise bed mobility for sexual positioning and transferring into and out of bed, and management of spasticity, such as by using a bolster between the knees for adduction spasticity. It may also include prescribed medications such as phosphodiesterase-5 inhibitors. Sexual rehabilitation may be provided by a range of appropriately trained health professionals within the multi-disciplinary team and may involve the stroke survivor or their partner alone, or the stroke survivor together with their partner. A range of formats may be used in sexual rehabilitation, including oral information, visual information, written materials, and audiovisual and practical training. Sexual rehabilitation may be provided short term (such as one-off counselling or a medication prescription) or longer term (such as cognitive-behavioural therapy targeting psychological and...
physical aspects of sex and intimacy (Song 2011), or physiotherapy to achieve mobility goals).

At present, several international guidelines recommend that sexual function should be assessed and managed following stroke (CSN 2014; NSF 2017; RCP 2018). However, these guidelines are largely based on consensus and do not address types of interventions or their relative effectiveness.

How the intervention might work
Pharmacological interventions such as phosphodiesterase-5 inhibitors, intracavernosal injections, and intraurethral suppositories assist with erectile function by increasing blood flow to the penis to achieve and maintain erection. Mechanisms of action vary with each medication; phosphodiesterase-5 inhibitors prevent the breakdown of cyclic guanosine monophosphate (cGMP), which results in enhancement of penile erection, and intracavernosal injections cause vasodilatation of the penis. Hormonal treatment, such as testosterone, can be provided to treat testosterone deficiency, resulting in improved libido and erectile function.

The range of non-pharmacological interventions is broad. Mechanical devices such as vacuum pumps and penile implants/penile prostheses treat erectile dysfunction via an external pump with a band to obtain and maintain an erection and surgical implantation of a prosthesis within the corpora cavernosa of the penis, respectively. Lubricating gels reducing friction between body parts, or between body parts and other objects, during sexual activity. Psycho-educational interventions (such as counselling and psychotherapy) may reduce anxiety related to sexual problems and provide reassurance around fears related to sexual activity precipitating another stroke, resulting in increased confidence in sexual abilities. Other therapies may work by providing practical guidance such as ideal timing (sexual activity in the morning when the person is not tired), management of bladder and bowel issues, and working around weakness (physical support with pillows) to help stroke survivors and their partners address problems that commonly affect sexuality after a stroke.

Complementary medicine interventions such as ginkgo biloba and ginseng may increase nitric oxide levels, leading to improved erectile function.

Why it is important to do this review
Sexual activity is an integral part of life, and the importance of addressing sexual health after stroke is well accepted (NSF 2018). Despite this, a recent Australian National Stroke Audit Rehabilitation Services Report showed that of 3613 post-stroke adults audited across 120 Australian public and private hospitals, only 20% received information on sexuality (NSF 2018). In addition, although current guidelines recommend assessment and management of post-stroke sexual dysfunction (NSF 2018), little is known about what types of interventions should be provided, and how effective these interventions are. Although some clinical studies and reviews (including Cochrane Reviews) have explored the role of these interventions for sexual dysfunction in conditions such as cancer (Miles 2007), chronic kidney disease (Vecchio 2010), cardiovascular disease (Byrne 2016), chronic obstructive pulmonary disease (COPD) (Levack 2015), and diabetes (Vardi 2007), the effectiveness and safety of these interventions in stroke survivors have not yet been studied thoroughly. This review therefore aims to identify existing evidence for interventions for sexual dysfunction in stroke survivors, and to identify gaps in current knowledge, with the purpose of informing health professionals, stroke survivors and their partners, and policy makers about the effectiveness of different interventions.

OBJECTIVES
To evaluate the effectiveness of interventions to reduce sexual dysfunction following stroke, and to assess adverse events associated with interventions for sexual dysfunction following stroke.

METHODS
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). We excluded cohort and cross-sectional studies.

Types of participants
We included all adults aged 18 years and over, regardless of gender, with stroke as defined by the World Health Organization (WHO) (Hatano 1976). We also included the partners of adults with stroke.

We included studies in which the cohort included a mix of stroke and non-stroke survivors if at least 75% of the study population consisted of stroke survivors. When less than 75% of the study population consisted of stroke survivors, we included these studies if data related only to the stroke population were separately reported.

Types of interventions
We included trials comparing pharmacological treatments, mechanical devices, or complementary medicine interventions with placebo and other non-pharmacological interventions with usual care. We also included trials with different forms of non-pharmacological interventions (such as a comprehensive individualised psycho-educational programme versus a basic/standard education pamphlet) for treating sexual dysfunction in stroke survivors.

Interventions could include but were not limited to:
- pharmacological interventions such as phosphodiesterase-5 inhibitors, intracavernosal injections, intraurethral suppositories, and hormonal therapy;
- non-pharmacological interventions, including:
  * mechanical devices (such as vacuum pumps, penile implants, penile prostheses, and lubricating gels);
  * psycho-educational interventions (such as counselling and psychotherapy). These could range from highly structured interventions provided by an appropriately trained health professional (medical practitioner, social worker, occupational therapist, sex therapist) to education...
alone provided through educational pamphlets from credible sources (such as by stroke associations); * established stroke consumer or professional associations as opposed to education from friends who have not undergone appropriate training to provide such education; and * physical therapy (such as physiotherapy for bed mobility) by appropriately trained personnel; and • complementary medicine interventions such as gingko biloba and ginseng.

We excluded uncontrolled and open drug intervention trials. Therefore, we would exclude a trial comparing pharmacological intervention to usual care. It is expected that the control comparator would be in the same category as the intervention. Pharmacological and complementary medicine interventions would be compared with placebo delivered via the same route as the intervention. However, other non-pharmacological interventions, such as counselling, could be provided at different intensities or in different formats (face-to-face versus group, written versus verbal). The key characteristic of an intervention is that the intention was to improve sexual dysfunction. We excluded studies in which the intervention might indirectly improve sexual dysfunction but was given primarily for another reason (such as an antidepressant for depression).

Types of outcome measures

Primary outcomes

Primary outcomes focused on sexual function or sexual satisfaction or both among stroke survivors and their partners.

Instruments that measure sexual function may include:

• International Index of Erectile Function (IIEF) (Rosen 1997);
• Derogatis Interview for Sexual Functioning (DISF) and Derogatis Interview for Sexual Functioning Self-Report (DISF-SR) (Derogatis 1997);
• Changes in Sexual Functioning Short-Form (CSFQ-14) (Keller 2006);
• Sexual Function Questionnaire (SFQ) (Quirk 2002); and
• Arizona Sexual Experience Scale (ASEX) (McGahuey 2000).

Instruments that measure sexual satisfaction may include:

• Sexual Self-Perception and Adjustment Questionnaire (SSPAQ) (Steinke 2013); and
• Sexual Satisfaction Scale for Women (SSS-W) (Meston 2005).

The primary outcomes of sexual function and sexual satisfaction were measured through the use of validated and non-validated instruments.

Secondary outcomes

Secondary outcomes focused on quality of life, psychological well-being (anxiety, depression, stress), satisfaction with intervention, sexual knowledge, and marital/relationship satisfaction (including partner satisfaction) among stroke survivors or their partners, or both. We also reported adverse events.

Instruments that measure quality of life may include:

• 36-item Short Form Health Survey (SF-36) or 12-item Short Form Health Survey (SF-12) [Ware 1992; Ware 1995]; and
• Stroke and Aphasia Quality of Life Scale-39 Generic (SAQOL-39g) (Hilarri 2003).

Instruments that measure psychological well-being may include:

• Depression, Anxiety, Stress Scale (DASS) (Lovibond 1995); and
• Hospital Anxiety and Depression Scale (HADS) (Zigmond 1983).

Instruments that measure marital/relationship satisfaction include:

• Evaluation and Nurturing Relationship Issues, Communication and Happiness (ENRICH) Marital Satisfaction (EMS) Scale (Olsen 1993).

We considered adverse events and side effects that may have resulted from the intervention. We defined serious adverse events as events that were life-threatening (including death) or required prolonged hospitalisation.

Search methods for identification of studies

See the 'Specialised register' information available at the Cochrane Stroke Group website. We searched for trials in all languages and arranged for translation of relevant articles when necessary.

Electronic searches

We conducted searches on 27 November 2019. We searched the Cochrane Stroke Group trials register and the following electronic databases.

• Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 11), in the Cochrane Library (Appendix 1).
• MEDLINE Ovid (from 1950) (Appendix 2).
• Embase Ovid (from 1980) (Appendix 3).
• Cumulative Index to Nursing and Allied Health Literature (CINAHL) EBSCO (from 1982) (Appendix 4).
• Allied and Complementary Medicine (AMED) Ovid (from 1985) (Appendix 5).
• PsycINFO Ovid (from 1806) (Appendix 6).
• Center for International Rehabilitation Research Information and Exchange (CIRRIE) Database of International Rehabilitation Research (http://cirrie.buffalo.edu/search/index.php) (Appendix 8).
• Database of Abstracts of Reviews of Effects (DARE), in the Cochrane Library (latest issue) (Appendix 9). Please note that DARE is no longer updated as of March 2018.
• ProQuest Dissertations & Theses Database (Appendix 10).
• OT Search by the American Occupational Foundation and the American Occupational Therapy Association (www1.aota.org/otsearch/) (Appendix 11).
• National Rehabilitation Information Center REHABDATA Database (www.naric.com/research/rehab/) (Appendix 13).
• SPORDiscus EBSCO (Appendix 14).
We developed the MEDLINE search strategy with the help of the Cochrance Stroke Group Information Specialist and adapted it for the other databases (Appendix 2). All search strategies deployed were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrance for identifying RCTs and controlled clinical trials (as described in the Cochrance Handbook for Systematic Reviews of Interventions (Higgins 2019)).

**Searching other electronic resources**

To identify further published, unpublished, and ongoing trials, we searched the following trials and research registers.

- World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch) (Appendix 16).
- ISRCTN Registry (www.isrctn.com) (previously known as Current Controlled Trials) (www.controlled-trials.com/) (Appendix 17).
- Trials Central (www.trialscentral.org/).
- Internet Stroke Center Stroke Trials Registry (www.strokecenter.org/trials).
- UK Clinical Research Network Portfolio database (public.ukcrn.org.uk/search/).

**Searching other resources**

To identify further published, unpublished, and ongoing trials, we:

- handsearched the reference lists of included trials and review articles about sexual rehabilitation after stroke;
- tracked citations using Web of Science Cited Reference Search for all included studies; and
- contacted experts active in this field (including authors of included trials and excluded studies identified as possible preliminary or pilot work).

**Data collection and analysis**

**Selection of studies**

Two review authors (LN, HS) independently screened titles and abstracts of references obtained as a result of our searching activities and excluded obviously irrelevant reports. We retrieved full-text articles for the remaining references and screened full-text articles, identified studies for inclusion, and recorded reasons for exclusion of ineligible studies. We resolved any disagreements through discussion. If required, we would have consulted a third review author (AB). We collated multiple reports of the same study so that each study - not each reference - would be the unit of interest in the review. We recorded the selection process and completed a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram when appropriate.

**Data extraction and management**

Two review authors (LN, HS) independently extracted data from included studies. We grouped studies by intervention type (pharmacological, non-pharmacological, and complementary medicine) when possible.

We used a pre-designed data extraction form to extract the following data from the included studies.

- Participants: number of participants, age, gender, baseline functional status, or level of impairment.
- Methods: inclusion criteria, time since stroke, and type, nature, and location of lesion.
- Interventions: description of interventions given to each treatment group including duration, type, dose, route of delivery, and frequency. For interventions provided by therapists,
  * we documented the discipline of the person providing the intervention (e.g. physician, occupational therapist, physiotherapist, psychologist, social worker).
- Outcomes: we documented primary and secondary outcomes relevant to this review. If a study used different methods for measuring the same outcome, we noted the outcome to be used for any subsequent analysis. We noted any important confounding variables. If more than two intervention groups were included in the study, we noted the method of including these groups in any subsequent analysis. The two review authors resolved any data extraction discrepancies through discussion. If disagreement persisted, we would have consulted a third review author (AB). We extracted data on whether adverse events were explicitly reported.

**Assessment of risk of bias in included studies**

Two review authors (LN, HS) independently assessed risk of bias for each study using the ‘Risk of bias’ tool outlined in the Cochrance Handbook for Systematic Reviews of Interventions (Higgins 2019). We resolved all disagreements by discussion. If required, we would have involved another review author (AB). We assessed the risk of bias according to the following seven domains.

- Random sequence generation.
- Allocation concealment.
- Blinding of participants and personnel.
- Blinding of outcome assessment.
- Incomplete outcome data.
- Selective outcome reporting.
- Other bias.

We graded the risk of bias for each domain as high, low, or unclear and provided information from the study report together with a justification for our judgement in the ‘Risk of bias’ tables.

**Measures of treatment effect**

We grouped studies by intervention type (pharmacological, non-pharmacological, and complementary medicine). Given the heterogeneity of interventions, we were not able to perform a meta-analysis. If it had been possible, we would have used the Cochrance Review Manager software to carry out statistical analyses to determine treatment effect (Review Manager 2014). For dichotomous variables, we would have calculated the treatment effect using a fixed-effect or random-effects model and reported it as odds ratios (ORs) with 95% confidence intervals (CIs). For continuous data, we would have calculated the treatment effect using standardised mean differences (SMDs) and 95% CIs when different studies used different scales to assess the same outcome, and we would have calculated mean differences (MDs) and 95% CIs when studies used the same method of measuring outcomes. We would have done this for all outcomes.
Unit of analysis issues

Unit of analysis issues did not arise with the included studies. If such issues had arisen, we would have addressed these as follows: if studies reported change values and the baseline value was not available, we would have used these data in meta-analyses but planned sensitivity analyses to investigate the effect of including these data. We would have handled adverse events as dichotomous variables. We would have done this for all outcomes.

Dealing with missing data

When an included study did not report a particular outcome but it had been included in the battery of measures administered, we contacted the study authors to ask for the original data. If we were unsuccessful in obtaining the data, we did not include that study in the analyses of that outcome.

When an included study had missing data (e.g. reports means but not standard deviations for follow-up data), we contacted study authors to ask for the missing data. If we were unsuccessful, we took logical steps to enter an assumed value. Such steps included estimating a standard deviation based on a reported standard error, estimating a follow-up standard deviation based on a baseline value, using the median as a proxy for the mean, and using a multiple of 0.75 times the interquartile range or 0.25 times the range as a proxy for the standard deviation values (Hozo 2005). We conducted sensitivity analyses to investigate the effect of entering assumed values.

Assessment of heterogeneity

If relevant, we would have used the I² statistic to measure heterogeneity among the trials in each analysis. When there was substantial heterogeneity (as defined by I² > 50%), we would have performed a meta-analysis using a random-effects model. If I² was less than or equal to 50%, we would have performed fixed-effect meta-analysis.

Assessment of reporting biases

We attempted to avoid reporting biases by using a comprehensive search strategy that included searching for unpublished studies and searching trials registers. We also assessed the completeness of outcome data.

Data synthesis

When we considered studies to be sufficiently similar, we would have conducted a meta-analysis by pooling the appropriate data using RevMan 5.3 (Review Manager 2014).

GRADE and 'Summary of findings'

It was not possible to perform quantitative meta-analysis due to the heterogeneity of studies; we used the GRADE approach instead to assess the quality of evidence (Higgins 2019). The GRADE approach defines quality of studies as the extent to which one can be certain that an estimate of effect is close to the quantity of interest. It specifies four levels of quality for a body of evidence for a given outcome: high, moderate, low, and very low. GRADE assessments of certainty are determined through consideration of the following five domains: risk of bias, inconsistency, indirectness, imprecision, and publication bias. Factors that may decrease the quality level of the included studies therefore include limitations in methods suggesting high likelihood of bias, indirectness of evidence such as with indirect populations, unexplained inconsistency of results, imprecision of results (e.g. with wide confidence intervals), and high probability of publication bias.

The main findings of the review, together with key information concerning the quality of evidence, are presented in the 'Summary of findings' tables. These findings are listed by intervention comparison in three categories (pharmacological interventions, non-pharmacological interventions, and complementary medicine interventions), with outcomes divided into primary outcomes (sexual function or sexual satisfaction, or both) and secondary outcomes (quality of life, psychological well-being, satisfaction with intervention, sexual knowledge, marital/relationship/partner satisfaction, and serious adverse events/death). When outcomes have not been addressed, we have reported this in the 'Summary of findings' table as "not addressed".

Subgroup analysis and investigation of heterogeneity

We would have explored heterogeneity by conducting additional subgroup analyses to investigate the effects of:

- time since stroke;
- type of intervention;
- level of impairment at baseline; and
- adherence with additional intervention.

Sensitivity analysis

We would have carried out a sensitivity analysis (when necessary) to explore the effects of the following methodological features.

- Allocation concealment: we would have re-analysed data, excluding trials with inadequate or unclear allocation concealment.
- Masking of outcome assessor: we would have re-analysed data, excluding trials without or with unclear masking of outcome assessor.
- Missing outcome data: we would have re-analysed data, excluding trials with inadequate or unclear methods of dealing with missing outcome data.

RESULTS

Description of studies

Results of the search

See Figure 1 - Study flow diagram.
Through searches, we identified 2776 citations (MEDLINE 370; Embase 1885; CENTRAL 203; AMED 28; CINAHL 35; PEDro 0; PROQUEST 39; PsycINFO 186; CT.gov 25; ICTR 0; SPORTDiscus 5; and CENTRAL 203). Two review authors (HS, LN) independently screened all citations. We selected 16 of these for full-text analysis, and both review authors assessed them for inclusion with no disagreement. Three studies met the inclusion criteria (Lu 2012; Ng 2017; Tibaek 2015). We excluded two as they were not RCTs (Chae 2006; Song 2011).

Included studies
See Characteristics of included studies.

The three included studies were undertaken in three countries (Australia, China, and Denmark); all were written in English except one (Lu 2012), which was presented as an abstract written in English, but the rest of the publication was written in Chinese and required translation. The studies involved a total of 212 participants. Most participants had had a stroke within the last three months (Lu 2012; Ng 2017). Participants in Tibaek 2015 had had their stroke more than one month before the study, but...
duration post stroke was not otherwise reported. Ng 2017 reported that participants in the study were of "broad cultural background"; however, no further information regarding this was provided, other than the proportion of participants who did not speak English as their first language. Lu 2012 and Tibaek 2015 did not describe the cultural background of their participants. Lu 2012 and Tibaek 2015 had male participants only, whereas Ng 2017 included participants of both sexes. The age range was very broad: in Ng 2017, age ranged from 19 to 95 years, whereas participants in Tibaek 2015 ranged from 57 to 75 years of age, and participants in Lu 2012 were young (aged 23 to 45 years).

The definition of sexuality varied between studies. Ng 2017 used a broad definition and included not just sexual intercourse but also masturbation, sexual thoughts, enjoying films with sexual content, etc., whereas Lu 2012 included only married participants who had had "regular sexual intercourse" pre-stroke. None of the studies described the sexual orientation and/or sexual identity of participants. As for involvement of sexual partners in the study, all studies recorded the proportion of participants who were married, although it should be noted that being married and having sexual partners were not necessarily linked. This ranged from 100% (n = 114) for Lu 2012, to 70% (n = 21 of 30) for Tibaek 2015, to 42.6% (n = 29 of 68) for Ng 2017. Only one study invited sexual partners to participate in the intervention (Ng 2017); however, study authors noted that none chose to do so. In Lu 2012, sexual partners were invited to participate as part of outcome measurement (sexual satisfaction of partner). Tibaek 2015 did not report involving sexual partners in intervention nor in outcome measurement.

With regards to setting, one study was conducted in the out-patient setting (Tibaek 2015), and one was conducted in an in-patient rehabilitation unit (Ng 2017). Lu 2012 appeared to have recruited participants from neurology in-patients, but it is assumed that a portion of the study occurred in the outpatient phase given the duration of the study (12 weeks), although this was not clearly stated in the study report.

In addition to the heterogeneity of participants, we noted the heterogeneity of interventions, which could be divided into pharmacological (sertraline) and non-pharmacological (psycho-educational and physical therapy) treatments. The trials varied in duration. In Ng 2017 and Tibaek 2015, the last assessment time point was six months post intervention, whereas in Lu 2012, it was four weeks post intervention. Tibaek 2015 and Lu 2012 collected end-of-intervention data, whereas Ng 2017 did not. The earliest post-intervention data were collected by Ng 2017 at six weeks following completion of the intervention.

**Pharmacological interventions**

Lu 2012 was the only study that assessed a pharmacological intervention. This study assessed the effectiveness of sertraline for secondary premature ejaculation after stroke in young men between 23 and 45 years of age. Lu 2012 recruited 114 male participants shortly after their stroke during their stay in a neurology in-patient unit. All participants were provided with "psychological and behavioural advice" by a neurologist and a urologist and were encouraged to engage in sexual activity frequently (one to two times a week). Study authors do not state the content, format, frequency, nor delivery method (verbal versus written) of this advice. In addition, the intervention group received 50 mg oral sertraline and the control group received 0.5 mg methylcobalamin. These medications were taken daily, four to six hours either before bed or before sexual activity, over the course of eight weeks. Assessment time points included baseline and four, eight, and 12 weeks from baseline. The eight-week assessment time point was therefore the end-of-intervention time point. Outcomes were measured with a mix of validated (intravaginal ejaculation latency time) and non-validated tools (sexual functioning, sexual satisfaction of participants' spouses). In addition, adverse effects of the medications were reported.

**Non-pharmacological interventions**

**Psycho-educational intervention**

One RCT compared the effectiveness of a structured sexual rehabilitation programme versus written education materials only (Ng 2017). The pilot study included 10 participants, and the larger subsequent study included data from those 10 and from an additional 58 participants, totalling 68 participants (Ng 2017). The mean age of participants was 63.3 years (range 19 to 95 years), and 57% were men. All participants had had a recent stroke and were undergoing in-patient rehabilitation. Both control and interventional groups received the National Stroke Foundation fact sheet "Sex and relationships after stroke" (NSF 2013), at the start of their in-patient rehabilitation, and the intervention group received a 30-minute individualised sexual rehabilitation programme from a rehabilitation physician later during their in-patient stay. Assessment time points were baseline, six weeks, and six months following the intervention. There was no "end-of-intervention" assessment time point. The following validated outcome measures were used: Sexual Functioning Questionnaire Short Form; Depression, Anxiety, Stress Scale; and Stroke and Aphasia Quality of Life Scale-39 Generic.

**Physical therapy intervention**

One study assessed the effectiveness of 12 consecutive weeks of pelvic floor muscle training by physiotherapists for lower urinary tract symptoms and erectile dysfunction in male stroke survivors (Tibaek 2015). This was compared to "normal standard general rehabilitation without specific treatment for lower urinary tract symptoms". This study recruited 31 men (median age 68 years). Assessment time points were baseline, three months from baseline, and six months after completion of the intervention. The three-month assessment time point was therefore the end-of-intervention time point. A mix of validated (International Index of Erectile Function Questionnaire) and non-validated (quality of life questions, termed "erectile dysfunction-induced bother" by the study author) measures were used.

**Complementary medicine intervention**

No studies were included.

**Excluded studies**

See Characteristics of excluded studies.

We excluded two trials as they were not RCTs and therefore did not fulfil inclusion criteria (Chae 2006; Song 2011). One was a clinical controlled trial conducted in Korea (n = 46), which compared a sexual rehabilitation programme involving both verbal and written information to standard care (Song 2011). The other was a case report of a trial of quetiapine for post-stroke hypersexuality and delusional jealousy in a 63-year-old South Korean man (Chae 2006).
Risk of bias in included studies

In assessing risk of bias, we attempted to contact the corresponding author for Lu 2012 for clarification because a large amount of information was not reported; however these attempts were unsuccessful. We have, therefore, based risk of bias assessments solely on published reports.

See Figure 2 - 'Risk of bias' summary.

Figure 2. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
Allocation

All included trials were described as randomised. In Lu 2012, randomisation was stated only in the abstract - not within the methods - nor was the method of randomisation described, so we judged this trial to be at unclear risk of bias. In Ng 2017, randomisation was performed via a computer-generated sequence by an independent statistician, and Tibaek 2015 randomised based on a mathematical table; therefore we judged Ng 2017 and Tibaek 2015 to be at low risk of bias. Allocation concealment through use of sealed envelopes was clearly stated in Ng 2017 and Tibaek 2015; therefore we judged Ng 2017 and Tibaek 2015 to be at low risk of bias. It is unclear through the publications whether allocation concealment occurred in Lu 2012, so we judged this trial to be at unclear risk of bias.

Blinding

It is unclear if participants, treating team, or outcome assessors were blinded in Lu 2012. No mention of blinding was made in the study, and there did not appear to be any attempt to ensure that sertraline and methylcobalamin tablets or their containers were matched in any way. We therefore judged this trial to be at high risk of bias. In Ng 2017 and Tibaek 2015, care providers and participants were not blinded but outcome assessors were blinded. We therefore judged these trials to be at high risk of bias with regards to blinding of participants and personnel but at low risk of bias with regards to blinding of outcome assessors. It is noted that blinding of participants and care providers in these two studies would not have been possible given the nature of the intervention.

Incomplete outcome data

All studies had dropouts; however, it is not clear from any of the studies how this was dealt with. Lu 2012 had a relatively low dropout rate in which only five of the total 114 participants (intervention group: 2, control group: 3) were lost to follow-up, which was less likely to have affected the overall findings. Tibaek 2015 also had a low dropout rate, with only one participant from the control group lost to lost-up. However, Tibaek 2015 had large quantities of missing data (13% of participants in the intervention group and 60% of participants in the control group did not complete their questionnaires). Poor self-reporting was postulated to occur because participants were male. Participant dropout in Ng 2017 (total participants n = 68) was significant at six months (n = 8, 11.7% at six weeks and n = 17, 25% at six months). The incomplete data for Tibaek 2015 and for Ng 2017 at six months would have significantly increased the risk of bias. We therefore judged Lu 2012 to be at unclear risk of bias and Tibaek 2015 and Ng 2017 to be at high risk of bias.

Selective reporting

There was no selective reporting in Ng 2017 and Tibaek 2015. However, Lu 2012 did not report measures related to clinical characteristics of participants (ECG findings; blood panel including "liver function tests, renal function tests, cholesterol, creatine kinase, hormone levels"; and blood pressure). We therefore judged Ng 2017 and Tibaek 2015 to be at low risk of bias and Lu 2012 to be at high risk of bias.

Other potential sources of bias

Tibaek 2015 had a small cohort (n = 30) and failed to reach the required sample size of 120 participants. Ng 2017 recruited 68 participants, which was above the pre-calculated sample size of 60 participants, and had 60 participants at six-week follow-up but only 51 (loss of 25%) at six-month follow-up. We judged Ng 2017 and Tibaek 2015 to be at low risk of bias. Lu 2012 had the largest cohort among the included studies (n = 114); however, as sample size calculations were not reported, it is unclear if this study was adequately powered.

Additionally, Lu 2012 provided very limited information on reasoning and few details for the intervention/control. For example, it is unclear as to why methylcobalamin was chosen as placebo (at an active dose at which side effects could be experienced), nor is information provided on the appearance of the medication and whether participants would have been able to determine what they received. It is also unclear as to what "psychological and behavioural advice" to the participants consisted of. The inclusion criteria for participants was highly subjective and poorly defined – for example, they had to have a "good relationship" with their wife. Finally, some of the outcome measures used in Lu 2012 were not validated instruments, but no information was provided with regards to these measures. Therefore we judged Lu 2012 to be at high risk of bias.

Effects of interventions

See: Summary of findings 1 Pharmacological interventions compared with placebo/usual care or different forms of intervention; Summary of findings 2 Non-pharmacological interventions compared with placebo/usual care or different forms of intervention; Summary of findings 3 Complementary medicine interventions compared with placebo/usual care or different forms of intervention

It was not possible to perform a meta-analysis of the results, given the heterogeneity of interventions and of outcome measures. The effect of interventions has been presented, grouped by intervention and then by outcomes.

Effects of interventions by intervention type

Pharmacological interventions

Lu 2012 (n = 114) compared the effectiveness of sertraline versus placebo (methylcobalamin) for secondary premature ejaculation after stroke in young Chinese men between 23 and 45 years of age. Based on the GRADE approach, this was a 'very low-quality' study given the high risk of bias.

The quality of evidence is 'very low' and suggests that use of sertraline to treat secondary premature ejaculation after stroke in young men may improve sexual function as measured by Intravaginal Ejaculatory Latency Time and by non-validated questionnaires on sexual function and sexual partner satisfaction in the short term (three months).

A large number of 'mild' adverse effects were reported in both intervention (20 of 58 participants) and control (11 of 56 participants) groups, with gastrointestinal side effects the most common (n = 9 intervention group, n = 6 control group).

Non-pharmacological interventions

Psycho-educational intervention

Ng 2017 (n = 68) compared the effectiveness of a structured sexual rehabilitation programme versus written education materials only.
in Australian stroke survivors with a mean age of 63.3 years. Based on the GRADE approach, this was a 'low-quality' study with high risk of bias.

The quality of evidence is therefore 'low', and evidence suggests that an individualised sexual rehabilitation programme compared to written educational materials alone does not further improve sexual functioning (as measured by Sexual Functioning Questionnaire Short Form), anxiety and depression (as measured by Depression, Anxiety, and Stress Score), quality of life (as measured by Stroke and Aphasia Quality of Life Scale-39 Generic), and functional independence (as measured by Functional Independence Measure) in the short term (six months).

Adverse events data were not provided.

**Physical therapy intervention**

Tibaek 2015 (n = 31) compared the effectiveness of 12 weeks of pelvic floor muscle training versus standard rehabilitation in male stroke survivors (median age 68 years) with lower urinary tract symptoms. Based on the GRADE approach, this was a 'very low-quality' study given the high risk of bias.

The quality of evidence is therefore 'very low', and evidence suggests that pelvic floor muscle training compared to standard rehabilitation does not further improve sexual function (as measured by International Index of Erectile Function Questionnaire) or quality of life (as measured by non-validated questionnaires termed "erectile dysfunction-induced bother" by the study author) in the short term (six months).

No adverse events were reported.

**Complementary medicine interventions**

No studies are included.

**Effects of interventions by outcomes**

**Primary outcomes**

Primary outcomes of sexual function and sexual satisfaction were measured through the use of validated and non-validated instruments.

**Sexual function**

**Sexual Functioning Questionnaire Short Form (CSFQ-14)**

Ng 2017 (n = 68) compared sexual rehabilitation to written education only and used the CSFQ-14 as the primary outcome. The CSFQ-14 includes questions measuring pleasure, frequency, interest, arousal, orgasm, and sexual functioning. Time points consisted of baseline, six weeks, and six months. There were no statistical differences in CSFQ-14 between groups at any of the time points. At six weeks, change score (z-score) was -0.31 (P = 0.758) (intervention median 26, interquartile ratio (IQR) 16.8 to 39; control median 28, IQR 16 to 40). At six months, change score (z-score) was -1.11 (P = 0.266) (intervention median 26, IQR 16.5 to 36.5; control median 35, IQR 18.5 to 41).

**International Index of Erectile Function Questionnaire (IIEF-5)**

Tibaek 2015 (n = 31) compared the effectiveness of pelvic floor muscle training to standard rehabilitation and used IIEF-5 as the primary outcome. The IIEF-5 is a five-question assessment tool (scores from 1 to 25) that measures the prevalence and severity of erectile dysfunction (Rosen 1997). Time points consisted of baseline, three months, and six months. Although there was intragroup improvement within the intervention group from baseline (median 18, IQR 5 to 24) to three months (median 20, IQR 5 to 25) (P = 0.04), there was no statistical significance for IIEF-5 between groups at any time point. At three months, median IIEF-5 score for the treatment group was 20 (IQR 5 to 25) and for the control group was 18 (IQR 5 to 25) (P = 0.84). At six months, median IIEF-5 score for the treatment group was 15 (IQR 5 to 25) and for the control group was 11 (IQR 5 to 18) (P = 0.08).

**Intravaginal Ejaculatory Latency Time (IELT)**

Lu 2012 (n = 114) compared the effectiveness of sertraline versus placebo (methylcobalamin) for secondary premature ejaculation and used IELT as a primary outcome measure. Intravaginal ejaculation latency time is measured time between the start of vaginal intercourse and the start of intravaginal ejaculation and is used to quantify premature ejaculation, although it should be noted that there is no uniform cut-off defining 'premature'. Expert consensus indicates one minute after penetration, and the International Classification of Diseases applies a cut-off of 15 seconds from the beginning of sexual intercourse (Serefolgu 2014). Time points consisted of baseline, four weeks, eight weeks, and 12 weeks. There was a significant increase in the intervention group compared to the control group at every time point. At four weeks, the intervention mean was 2.9 (standard deviation (SD) 0.5) compared to 2.1 for the control (SD 0.4) (P < 0.01). At eight weeks, the intervention mean was 5.8 (SD 0.7) compared to 3.8 for the control (SD 0.5) (P < 0.01). At 12 weeks, the intervention mean was 6.1 (SD 0.9) compared to 4.5 for the control (SD 0.7) (P < 0.01) (Analysis 1.1).

**Non-validated measures - sexual functioning**

In addition to IELT, Lu 2012 used a non-validated measure for 'sexual functioning'; however, no information (such as questions or scoring) was provided with regards to this measure. Time points consisted of baseline, four weeks, eight weeks, and 12 weeks. There was a significant increase in the intervention group compared to the control group at every time point. At four weeks, the intervention mean was 5.9 (SD 1.9) compared to 4.4 for the control (SD 2.1) (P < 0.01). At eight weeks, the intervention mean was 7.2 (SD 2.2) compared to 5.3 for the control (SD 1.9) (P < 0.01). At 12 weeks, the intervention mean was 8.3 (SD 2.2) compared to 6.5 for the control (SD 2.7) (P < 0.01) (Analysis 1.2).

**Sexual satisfaction**

This was not measured.

**Secondary outcomes**

Secondary outcomes were quality of life, psychological functioning, satisfaction with sexual rehabilitation services, sexual knowledge, marital/relationship/partner sexual satisfaction, and adverse events.

**Quality of life**

**Stroke and Aphasia Quality of Life Scale-39 Generic (SAQOL-39g)**

Ng 2017 (n = 68) compared sexual rehabilitation to written education only and used the SAQOL-39g to assess the quality of life at baseline, at six weeks, and at six months. The SAQOL-39g
Sexual dysfunction is a common problem among stroke survivors. It is often multi-factorial; this is reflected in the broad range of available pharmacological and non-pharmacological interventions. The aims of this review were to determine existing evidence for the effectiveness and safety of these interventions in stroke survivors, to identify gaps in current knowledge, and to recommend future directions. We identified three randomised controlled trials (RCTs) with a total of 212 participants that addressed the effectiveness of interventions for sexual dysfunction following stroke. All trials had short-term outcomes (up to six months). Due to the heterogeneity of the interventions, we were unable to perform any mathematical or statistical direct or indirect comparisons across RCTs. Instead, we used the GRADE approach to provide a best-evidence synthesis based on the quality of evidence. Results are as follows.

- Based on one 'very low-quality' small RCT (Lu 2012), data are insufficient to provide any reliable indication of benefit or risk with the use of sertraline for improving secondary premature ejaculation and sexual satisfaction in young male stroke survivors.
Based on one ‘low-quality’ small RCT (Ng 2017), data are insufficient to provide any reliable indication of benefit or risk of sexual rehabilitation programmes in an inpatient rehabilitation setting for improving sexual dysfunction.

Based on one ‘very low-quality’ small RCT (Tibaek 2015), data are insufficient to provide any reliable indication of benefit or risk of physical therapy targeted towards pelvic floor muscles for improving erectile function following stroke.

No study participants reported any adverse events from pelvic floor therapy (Tibaek 2015). No adverse event data were provided by the authors of the Ng 2017 trial. A large number of ‘mild’ adverse effects (predominantly gastrointestinal) were reported with the use of sertraline (Lu 2012).

Overall completeness and applicability of evidence

Only RCTs were included in this review, and there was a paucity of literature in general. Many pharmacological interventions are used in clinical practice, but only one included RCT examined a pharmacological intervention (Lu 2012), and the medication studied (sertraline) is not one that is commonly used in clinical practice to treat sexual dysfunction. On the contrary, one of the well-recognised side effects of sertraline is sexual dysfunction (reduced libido) itself. There was no commonality in the two non-pharmacological RCTs (one described sexual rehabilitation consisting predominantly of education and counselling, and the other described pelvic floor physiotherapy), and no results could be pooled (Ng 2017). Further, no studies addressed the numerous other interventions (including devices and complementary medicine) used to manage sexual dysfunction.

A limited number of outcomes were addressed, for example, sexual satisfaction, satisfaction with sexual rehabilitation services, and sexual knowledge were not addressed by any of the included studies. The impact of sexual dysfunction on sexual partners is also significant, but there was little involvement of partners, and only one of the three RCTs included an outcome measure for sexual partners (Lu 2012). There was no reporting of gender identification nor sexual orientation, and particular populations such as those who identify as lesbian, gay, bisexual, transgender, intersex, and queer (LGBTIQ+) may be particularly vulnerable, at higher risk of stigma, and less well supported. According to the Australian Department of Health (AIHW 2018), up to 11% of the Australian population identify as LGBTIQ+, representing a significant yet under-studied population.

No recommendations can be made regarding any specific treatment for sexual dysfunction following stroke based on current evidence. Evidence is limited by the small number of low- to very low-quality trials. Additionally, the RCT with the largest number of participants (N = 114) had the most restrictive participant characteristics (young, married, heterosexual Chinese males), making it impossible to generalise the results (Lu 2012).

Sexuality is an area in which the attitudes of many - patients and clinicians included - make management and research into this area challenging (Steinke 2013). Older patients, patients who do not identify as heterosexual, and patients without partners may be particularly wary of the social stigma reflected in society at large (Steinke 2013). All included trials however have been published in the past decade, which is encouraging, as this suggests that researchers have identified lack of evidence to support clinical practice in this area and are beginning to address it. As there is a cultural shift towards more open discussion about sexuality, this may also facilitate the willingness of participants to be involved in research. An Australia-based research group led by McGrath et al recently published findings from a survey done with 102 participants (stroke survivors and their partners, rehabilitation clinicians, and researchers in the field) using modified Delphi methods (McGrath 2019). A high degree of consensus was evident amongst the participants that 18 core content areas should be prioritised for inclusion in sexual rehabilitation following stroke, and that sexual rehabilitation should be offered in the subacute and chronic phases of stroke recovery. Participants also expressed a preference for health professionals to deliver the intervention in a face-to-face format. It is likely that these findings will be used to prioritise the content of, and approaches to, sexual rehabilitation, thus paving the way for further interventional research.

Quality of the evidence

We identified three RCTs. All were at high risk of bias. It is recognised, however, that it would be difficult to blind participants when interventions such as counselling or therapy are provided. All studies included small sample sizes and poor reporting, and lack of clarification from study authors made it challenging to fully determine the risk of bias. This was particularly challenging with Lu 2012, in which a large amount of information, including participant characteristics, method of randomisation, allocation concealment, and blinding, was unclear. Reporting of the intervention/control itself was also unclear and was not consistent with CONSORT guidelines (Schulz 2011).

Potential biases in the review process

We applied a comprehensive search strategy and included searches of clinical trial registers and grey literature. We also contacted experts in the field. It is possible however that we may have missed relevant studies. Two of the three included RCTs were negative studies (Ng 2017; Tibaek 2015), which was a positive given the tendency for negative studies not to be published, resulting in publication bias.

Agreements and disagreements with other studies or reviews

The findings of this review are consistent with those of previous systematic and literature reviews on sexuality following stroke. In addition to determining the effectiveness of interventions for sexual dysfunction, Dusenbury 2017 and Grenier-Genest 2017 described the determinants of sexual dysfunction. Dusenbury 2017 reported that most studies included male participants (90%) with moderate erectile dysfunction (ED) and mild depression. Changes in sexual activity, sexual dissatisfaction, and sexual dysfunction were common and were much worse post stroke (Dusenbury 2017). Specific changes included decreased libido, problems with orgasm, and erectile dysfunction (Dusenbury 2017). A further literature review focused on the anatomy and physiology of sexual dysfunction post stroke (Park 2015). No reviews included Lu 2012, likely because this study was listed only on the CENTRAL database and therefore could be easily missed.

Other Cochrane Reviews have explored the effectiveness of interventions for sexual dysfunction in various conditions. Vecchio 2010 included 15 studies (8 parallel, 7 cross-over; 352 patients) that evaluated the effects of phosphodiesterase-5 inhibitor (PDE5i) agents, zinc, vitamin E, vitamin D, or bromocriptine compared to
placebo. Of these interventions, review authors concluded that two (PDE5i and oral zinc) were likely to confer some benefit. Review authors found that PDE5 inhibitors improved erectile function in people with chronic kidney disease; however, the quality of this evidence was limited by the small number of trials (3 trials, 142 patients). The quality of evidence supporting oral zinc supplementation for increased frequency and potency of intercourse was even weaker, with only one small trial (20 patients). Xiao 2012 found limited evidence based on two trials (420 participants in total) - both judged to have high risk of attrition bias - that sildenafil improved erectile function in people with multiple sclerosis. Levack 2015 included two studies involving a total of 48 participants, which evaluated the effects of interventions for sexual dysfunction in people with chronic obstructive pulmonary disease (COPD). These studies investigated different interventions - one compared testosterone therapy to placebo, and the other compared one month of long-term oxygen therapy to a single 24-hour dose of oxygen therapy. Review authors concluded that there was low-quality evidence suggesting that testosterone therapy for men with COPD resulted in improvements in erectile function, but that data were insufficient to provide any reliable indication of benefit or risk to guide clinical practice. Although some of these treatments are likely to have a similar effect in people with stroke, evidence to support this is required.

It is interesting that most studies have focused on erectile dysfunction, which automatically excludes the sexual experience of all women. Erectile dysfunction is only one aspect of sexuality, which, as previously mentioned, is a broad concept and may be experienced and expressed in a variety of ways (WHO 2006). It is challenging to study interventions that consider sexuality as the broad concept that it is. The broad concept of sexuality brings with it a further challenge, which is that of outcome measurement. Although outcome measures, such as the Changes in Sexual Functioning Questionnaire Short Form-14 (CSFQ-14) (Keller 2006), address sexuality broadly, these have not been validated in the stroke population and probably are not sensitive enough or adequately targeted for this population, for example, the effects of hemiplegia or language deficits are not considered within the questionnaire. A comprehensive, stroke-specific tool is needed to gather accurate response data.

A U T H O R S ' C O N C L U S I O N S

Implications for practice

A paucity of evidence is available from RCTs on the effectiveness of interventions to treat sexual dysfunction in the post-stroke population. However, the absence of evidence should not be interpreted as proof of ineffectiveness.

Based on current evidence, data are insufficient to provide any reliable indication of benefit or risk to guide clinical practice in terms of the use of sertraline, specific pelvic floor muscle training, or individualised sexual rehabilitation.

Implications for research

This overview has highlighted a significant gap in the current literature. There is need for:

• appropriate study designs, robust methods, and longitudinal data that address the multi-faceted and inherently sensitive nature of sexuality;
• studies to assess the effectiveness of the broad range of interventions used to manage sexual dysfunction;
• studies to assess the appropriate timing, content, and delivery of rehabilitation interventions;
• development of stroke-specific reliable and validated outcome measures that reflect the broad concept of sexuality;
• studies specifically designed for women with stroke; and
• recognition and inclusion of participants with diverse sexuality backgrounds, including those who identify as LGBTQ+ and sexual partners in general.

A C K N O W L E D G E M E N T S

We acknowledge the Cochrane Stroke Group, in particular Joshua Cheyne (searcher and reviewer) and Hazel Fraser, for their assistance. We thank Nina Zhang and Fary Khan for reading the draft of the protocol, and Lai Kiap Lim for assisting with translation of the study by Lu et al (2012). We thank the reviewers, Maree Hackett, Peter Langhorne, Areyelly Rodriguez, Margaret McGrath, Abhijna Vithal Yergolkar, and Nji Mbaka Fon for their thoughtful and constructive comments.
References to studies included in this review

Lu 2012 [published data only] http://dx.doi.org/10.3969/j.issn.1008-0648.2012.03.014


Ng 2017 [published data only] http://dx.doi.org/10.2340/16501977-2219


Tibaek 2015 [published data only]


References to studies excluded from this review

Chae 2006 [published data only]


Song 2011 [published data only] https://dx.doi.org/10.3233/NRE-2011-0642


Additional references

ABS 2017


AIHW 2018


AIHW 2019


Byrne 2016


CDC 2017


CSN 2014


Derogatis 1997


Dusenbury 2017


Giaquinto 2003


Greiner-Genest 2017


Hatano 1976


Higgins 2019


Hilari 2003

Interventions for sexual dysfunction following stroke (Review)

Monga 1986

NSF 2013

NSF 2017

NSF 2018

Olsen 1993

Palmer 2005

Park 2015

Quirk 2002

RCP 2016

Review Manager 2014 [Computer program]

Rosen 1997
Schmitz 2010

Schulz 2011

Serefoğlu 2014

Sjogren 1981

Stein 2013

Steinke 2013

Tamam 2008

Vardi 2007

Vecchio 2010

Wade 1992

Ware 1992

Ware 1995

WHO 2006

Xiao 2012

Zigmond 1983

Characteristics of included studies [ordered by study ID]

**Study characteristics**

<table>
<thead>
<tr>
<th>Study characteristics</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Study design: RCT</td>
</tr>
<tr>
<td></td>
<td>Study duration: 12 weeks</td>
</tr>
<tr>
<td></td>
<td>Follow-up: 4 weeks, 8 weeks, 12 weeks</td>
</tr>
<tr>
<td></td>
<td>Country: China</td>
</tr>
</tbody>
</table>

References to other published versions of this review

Ng 2014

* Indicates the major publication for the study
Setting: presumed outpatients given duration of study, although initial recruitment was sought from neurology inpatients

Participants

Number (intervention/control): 58/56
Age (mean): 41 years
Sex (both groups): 100% men

Inclusion criteria

- Married men with "good relationship with their wives"
- Age between 23 and 45
- Previous regular sexual intercourse with no issues with premature ejaculation
- Within 3 months post stroke, more than 75% of sexual intercourse resulting in premature ejaculation - either intravaginal ejaculatory latent time less than 2 minutes or ejaculation within 15 penetrations
- Stroke confirmed on MRI less than 3 months before
- International Index of Erectile Function Questionnaire < 21

Exclusion criteria

- Surgery that could affect sexual function
- Recent and ongoing use of medications with known association with sexual dysfunction
- Unstable Grade 3 hypertension, coronary heart disease, anxiety
- Neurologist or urologist advice - not appropriate for sexual activity

Interventions

Treatment group: 8 weeks of oral sertraline 50 mg daily 4 to 6 hours before bed or sexual intercourse. Participants encouraged to have sexual intercourse at least 1 to 2 times weekly Neurologist and urologist provided psychological and behavioural advice
Control group: 8 weeks of oral methylcobalamin 0.5 mg daily 4 to 6 hours before bed or sexual intercourse
All participants received "psychological and behavioural advice" from a neurologist and urologist and were encouraged to have sexual intercourse at least 1 to 2 times weekly

Outcomes

- Intravaginal ejaculatory latent time
- Assessment of sexual satisfaction of partner
- Self-scored sexual functioning questionnaire
- Blood panel including "liver function tests, renal function tests, cholesterol, creatine kinase, hormone levels"
- Blood pressure
- ECG
- Adverse reactions

Funding source

Funding is not stated

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Randomisation is mentioned in the abstract; method is not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>High risk</td>
<td>Not stated</td>
</tr>
</tbody>
</table>
### Lu 2012 (Continued)

<table>
<thead>
<tr>
<th>Bias/Other</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Blinding is not stated. No attempt was made to ensure sertraline and methylcobalamin tablets or their containers are matched in any way.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>2 dropouts from treatment group and 3 from control group. Unclear how missing data were handled</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>No reporting of outcome measures such as ECG findings, blood panel including &quot;liver function tests, renal function tests, cholesterol, creatine kinase, hormone levels,&quot; and blood pressure</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Patient characteristics are not reported. Other than IELT, other outcome measures are not validated in stroke populations nor described. Screening process for recruitment of patients is unclear. Some criteria (such as 'good relationship') were not clearly defined. Setting is unclear: patients were recruited as inpatients, but it is unclear if and how much of the programme was continued in an outpatient setting. No information on psychological and behavioural advice given was provided. Unclear as to why methylcobalamin was chosen as the control.</td>
</tr>
</tbody>
</table>

### Ng 2017

#### Study characteristics

<table>
<thead>
<tr>
<th>Methods</th>
<th>Single-blinded RCT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study duration: 14 months</td>
</tr>
<tr>
<td></td>
<td>Follow-up: 6 weeks, 6 months</td>
</tr>
<tr>
<td></td>
<td>Country: Australia</td>
</tr>
<tr>
<td></td>
<td>Setting: inpatient rehabilitation unit</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
<th>Number (intervention/control): 35/33</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (intervention/control):</td>
<td>62/67 years</td>
</tr>
<tr>
<td>Sex (intervention/control):</td>
<td>60%/54.5% men</td>
</tr>
</tbody>
</table>

**Inclusion criteria**

- Age ≥ 18
- Confirmed diagnosis of stroke (haemorrhagic or ischaemic) based on clinical examination and imaging as assessed by a neurologist
- Ability to comprehend (FIM comprehension score ≥ 4)
- Ability to give informed consent

**Exclusion criteria**

- Severe cognitive issues
- Dementia
- Medical instability
- Inability to speak English and no interpreter available
Interventions

Treatment group: single 30-minute individualised sexual rehabilitation programme provided by a rehabilitation physician and written educational material (National Stroke Foundation fact sheet). Partners were included when possible

Rehabilitation physicians delivering the individualised component of the programme had 7 years of experience each in delivery of sexual rehabilitation. Additional input from occupational therapy, physiotherapy, and or psychology as required, for counselling or training to optimise bed mobility for sexual positioning or to address other aspects of sexuality. Programmes were individually tailored and based on the "PLISSIT" model: Permission - reassurance that sexual dysfunction is common; Limited information - such as safety of resuming sexual activity; Specific Suggestions - such as positioning; and Intensive Therapy - such as in-depth counselling. Intensive therapy was not provided as part of the 30-minute session, but participants could be referred when deemed appropriate by the participant and the physician. Content included (1) information regarding common changes in sexuality post stroke; (2) counselling on fears regarding post-stroke sexuality; (3) challenging stereotypical views on sexuality and sexual satisfaction (such as sexual intercourse being the only expression of sexual activity, having sexual intercourse only at night, or believing that sexual intercourse must be spontaneous to achieve sexual satisfaction); and (4) tips and strategies to minimise post-stroke sexual dysfunction, such as choosing a suitable time, reviewing sexual side effects from medications, finding safe and comfortable sexual positions, and managing reduced vaginal lubrication, urinary continence issues, or erectile difficulties

Control group: written educational material only (National Stroke Foundation fact sheet). Could request additional information if desired

Outcomes

• CSFQ-14: primary outcome
• DASS
• FIM
• SAQOL-39g

Funding source
Victor Hurley Medical Research Grant-in-Aid and the AFRM Ipsen Open Research Fellowship

Notes
This study included data from its pilot study. A large proportion of the intervention group were not sexually active with a partner

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Stated: &quot;randomized ... using a computer-generated sequence by an independent statistician&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Consecutively numbered, opaque, sealed envelopes were used for allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Participants and care providers were not blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Assessors were blinded and had no access to previous treatments or documentation</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>Participant dropout of 11% at 6 weeks and 25% at 6 months was reported. How this was addressed in terms of data handling was not stated</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All outcomes are reported</td>
</tr>
</tbody>
</table>
Ng 2017 (Continued)

Other bias Low risk Study was adequately powered

Tibaek 2015

Study characteristics

Methods
Study design: RCT
Study duration: 35 months
Follow-up: 3 months, 6 months
Country: Denmark
Setting: outpatient

Participants
Number (intervention/control): 15/15
Median age (intervention/control): 68/70 years
Sex (intervention/control): 100% men
Inclusion criteria
- Confirmed diagnosis of stroke by WHO criterion or imaging over 1 month in the past
- LUTS according to International Continence Society definition beginning or made worse around the time of stroke
- Ability to walk independently indoors for 100 metres
- Independent toileting
- Age over 18
- MMSE over 25
Exclusion criteria
- Prior LUTS surgery
- Pelvic surgery or pelvic trauma
- More than 2 diagnosed strokes
- Severe neurological disorder (e.g. dementia)
- Severe dysphagia
- Severe psychiatric disease
- Prostate cancer
- Inability to speak either Danish or English

Interventions
Treatment group: PFMT programme delivered by a specialised physiotherapist consisting of:
- information on anatomy, physiology, and purpose of PFMT;
- home exercises: strengthening with maximum contraction and endurance over time;
- group treatments similar to home treatments but including PFMT during coughing, sneezing, and various daily activities;
- all activities repeated 4 to 8 times in supine, standing, and sitting positions and during walking;
- digital anal palpation of PFM performed to provide feedback and ensure correct contraction; and
- treatment over 12 consecutive weeks, daily exercises 1 to 2 per day, digital anal palpation only 2 to 3 times total.
Control group received:
- standard rehabilitation programme without specific treatment for LUTS.

Outcomes
- IIEF-5
- Erectile dysfunction-induced bother questions
Funding source

Funding sources: grants from the Association of Danish Physiotherapists Research Foundation, the Association of Danish Physiotherapists Practise Foundation, the Foundation of 12.12.1981, Lykkefeldts Grant, the Foundation of Lundbeck, and the Department of Physiotherapy and Occupational Therapy Glostrup Hospital, University of Copenhagen

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection</td>
<td>Low risk</td>
<td>Stated: &quot;randomisation was based on a mathematical table, delivered in sealed envelope&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Sealed envelopes were used for allocation concealment</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Participants were not blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>Assessors were not blinded</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>6% were lost to follow-up, but a large quantity of data was missing due to failure to complete questionnaires (17% in treatment group and 40% to 60% in control group) It is unclear how missing data were managed</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All outcomes were reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Did not reach sample size of 120 participants</td>
</tr>
</tbody>
</table>

CSFQ-14: Changes in Sexual Functioning Questionnaire Short Form-14.
DASS 21: Depression, Anxiety, and Stress Scale.
ECG: electrocardiogram.
FIM: Functional Independence Measure.
IELT: intravaginal ejaculatory latency time.
IIEF-5: International Index of Erectile Function Questionnaire.
LUTS: lower urinary tract symptoms.
MMSE: Mini-Mental State Examination.
MRI: magnetic resonance imaging.
PFM: pelvic floor muscle.
PFMT: pelvic floor muscle training.
RCT: randomised controlled trial.
SAQOL-39g: Stroke Aphasia Quality of Life Scale-39 Generic.
WHO: World Health Organization.

Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chae 2006</td>
<td>Case report: not RCT</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>Song 2011</td>
<td>CCT: not RCT</td>
</tr>
</tbody>
</table>

CCT: clinical controlled trial. RCT: randomised controlled trial.

**DATA AND ANALYSES**

**Comparison 1. Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention**

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Sexual function - intravaginal ejaculatory latent time</td>
<td>1</td>
<td>114</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>2.00 [1.78, 2.22]</td>
</tr>
<tr>
<td>1.2 Sexual function - non-validated measure</td>
<td>1</td>
<td>114</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>0.90 [0.15, 1.65]</td>
</tr>
<tr>
<td>1.3 Partner sexual satisfaction - non-validated measure</td>
<td>1</td>
<td>114</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>2.50 [1.89, 3.11]</td>
</tr>
<tr>
<td>1.4 Adverse effects</td>
<td>1</td>
<td>114</td>
<td>Odds Ratio (M-H, Fixed, 95% CI)</td>
<td>2.15 [0.92, 5.05]</td>
</tr>
</tbody>
</table>

**Analysis 1.1. Comparison 1: Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention, Outcome 1: Sexual function - intravaginal ejaculatory latent time**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Sertraline Mean</th>
<th>Sertraline SD</th>
<th>Sertraline Total</th>
<th>Placebo (methylcobalamin) Mean</th>
<th>Placebo (methylcobalamin) SD</th>
<th>Placebo (methylcobalamin) Total</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu 2012</td>
<td>5.8</td>
<td>0.7</td>
<td>58</td>
<td>3.8</td>
<td>0.5</td>
<td>56</td>
<td>2.00 [1.78, 2.22]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td></td>
<td>58</td>
<td></td>
<td></td>
<td>100.0%</td>
<td>2.00 [1.78, 2.22]</td>
</tr>
<tr>
<td>Heterogeneity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Favour placebo (methylcobalamin)</td>
</tr>
<tr>
<td>Test for overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Favour sertraline</td>
</tr>
<tr>
<td>effect: Z = 17.60 (P &lt; 0.00001)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>differences: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Analysis 1.2. Comparison 1: Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention, Outcome 2: Sexual function - non-validated measure**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Sertraline Mean</th>
<th>Sertraline SD</th>
<th>Sertraline Total</th>
<th>Placebo (methylcobalamin) Mean</th>
<th>Placebo (methylcobalamin) SD</th>
<th>Placebo (methylcobalamin) Total</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu 2012</td>
<td>6.2</td>
<td>2.2</td>
<td>58</td>
<td>5.3</td>
<td>1.9</td>
<td>56</td>
<td>0.90 [0.15 , 1.65]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td></td>
<td></td>
<td>58</td>
<td></td>
<td></td>
<td>100.0%</td>
<td>0.90 [0.15 , 1.65]</td>
</tr>
<tr>
<td>Heterogeneity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Favour placebo (methylcobalamin)</td>
</tr>
<tr>
<td>Test for overall</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Favour sertraline</td>
</tr>
<tr>
<td>effect: Z = 2.34 (P = 0.02)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for subgroup</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Favour placebo (methylcobalamin)</td>
</tr>
<tr>
<td>differences: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Favour sertraline</td>
</tr>
</tbody>
</table>
Analysis 1.3. Comparison 1: Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention, Outcome 3: Partner sexual satisfaction - non-validated measure

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Sertraline</th>
<th>Placebo (methylcobalamin)</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu 2012</td>
<td>13.3</td>
<td>10.8</td>
<td>2.50 [1.89, 3.11]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>58</td>
<td>56</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Not applicable
Test for overall effect: Z = 8.08 (P < 0.00001)
Test for subgroup differences: Not applicable

- Favours placebo (methylcobalamin)
- Favours sertraline

Analysis 1.4. Comparison 1: Sertraline compared with placebo (methylcobalamin) for secondary premature ejaculation after stroke - end of intervention, Outcome 4: Adverse effects

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Sertraline</th>
<th>Placebo (methylcobalamin)</th>
<th>Odds Ratio M-H, Fixed, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu 2012</td>
<td>20</td>
<td>11</td>
<td>2.15 [0.92, 5.05]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>58</td>
<td>56</td>
<td></td>
</tr>
</tbody>
</table>

Total events: 20 and 11
Heterogeneity: Not applicable
Test for overall effect: Z = 1.76 (P = 0.08)
Test for subgroup differences: Not applicable

A P P E N D I C E S

Appendix 1. CENTRAL search strategy

#1 MeSH descriptor: [Cerebrovascular Disorders] this term only
#2 MeSH descriptor: [Basal Ganglia Cerebrovascular Disease] this term only
#3 MeSH descriptor: [Brain Ischemia] explode all trees
#4 MeSH descriptor: [Carotid Artery Diseases] explode all trees
#5 MeSH descriptor: [Carotid Artery Diseases] explode all trees
#6 MeSH descriptor: [Intracranial Arterial Diseases] explode all trees
#7 MeSH descriptor: [Intracranial Embolism and Thrombosis] explode all trees
#8 MeSH descriptor: [Intracranial Hemorrhages] explode all trees
#9 MeSH descriptor: [Stroke] explode all trees
#10 MeSH descriptor: [Vasospasm, Intracranial] this term only
#11 MeSH descriptor: [Vertebral Artery Dissection] this term only
#12 (stroke* or poststroke or apoplex* or cerebral vas* or brain vasc* or cerebrovasc* or cva* or SAH):ti,ab,kw (Word variations have been searched)
#13 ((brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle cerebral artery or MCA* or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying) near/5 (isch? emi* or infarct* or thrombo* or emboli* or occlus* or hypoxi*)):ti,ab,kw (Word variations have been searched)
#14 ((brain* or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli* or putaminal or putamen or posterior fossa or hemispher* or subarachnoid) near/5 (h?emorrhag* or h? ematoma* or bleed*)):ti,ab,kw (Word variations have been searched)
#15 MeSH descriptor: [Hemiplegia] this term only
#16 MeSH descriptor: [Paresis] explode all trees
#17 MeSH descriptor: [Gait Disorders, Neurologic] explode all trees
#18 MeSH descriptor: [Aphasia] explode all trees
#19 MeSH descriptor: [Hemianopsia] this term only
#20 (hemipleg* or hemipar* or paresis or paraparesis or paretic):ti,ab,kw (Word variations have been searched)
#21 (or #1-#20)
#22 MeSH descriptor: [Sexual Behavior] explode all trees
Appendix 2. MEDLINE search strategy

1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp cerebrovascular trauma/ or exp intracranial arterial diseases/ or exp intracranial arteriovenous malformations/ or exp "intracranial embolism and thrombosis"/ or exp intracranial hemorrhages/ or stroke/ or exp brain infarction/ or stroke, lacunar/ or vasospasm, intracranial/ or vertebral artery dissection/

2. (stroke$ or post stroke or poststroke or post-stroke or apoplex$ or cerebral vasc$ or cerebrovasc$ or cva or SAH).tw.

3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery) adj5 (isch?em i$ or infarct$ or thrombo$ or emboli$ or occlus $ or hypoxi$)).tw.

4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h?emorrhag$ or h? ematoma$ or bleed$)).tw.

5. exp hemiplegia/ or exp paresis/ or gait disorders, neurologic/

6. exp aphasia/ or hemianopsia/

7. (hempar$ or hemipleg$ or paresis or paretic or aphas* or dysphas$ or hemianop$).tw.

8. or/1-7

9. exp sexual behavior/ or sex counseling/ or libido/ or exp sexual dysfunction, physiological/ or exp sexual dysfunctions, psychological/ or sexual partners/

10. ((sexual$ or libido) adj5 (disorder$ or declin$ or dysfunct$ or impair$ or deficit$ or disabilit$ or problem$ or concern$ or difficult$)).tw.

11. (sexual$ adj5 (activ$ or health or issue$ or satisfaction or function$ or experience$ or adjustment or chang$ or knowledge or relation$ or skill$ or intercourse or interest$ or wish$ or need$ or behav$ or perform$ or spouse or partner or wife or husband$)).tw.

12. (sexual$ adj5 (therap$ or treat$ or rehab$ or train$ or counsel$ or psycholog$ or psychother$ or physiotherap$ or help$ or advi$ or inform$ or guid$ or intervention$ or educat$)).tw.

13. (erectile adj3 (function$ or dysfunction$)).tw.

14. (intima$ adj3 (relation$ or spouse or partner or wife or husband$)).tw.


16. 9 or 10 or 11 or 12 or 13 or 14 or 15

17. Randomized Controlled Trials as Topic/

18. random allocation/

19. Controlled Clinical Trials as Topic/
20. control groups/
21. clinical trials as topic/
22. double-blind method/
23. single-blind method/
24. Placebos/
25. placebo effect/
26. cross-over studies/
27. Drug Evaluation/ or drug therapy.fs.
28. therapies, investigational/ or research design/
29. randomized controlled trial.pt.
30. controlled clinical trial.pt.
31. clinical trial.pt.
32. (random$ or RCT or RCTs).tw.
33. (controlled adj5 (trial$ or stud$)).tw.
34. (clinical$ adj5 trial$).tw.
35. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
36. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
37. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
38. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
39. (cross-over or cross over or crossover).tw.
40. (placebo$ or sham).tw.
41. trial.tw
42. (assign$ or allocat$).tw.
43. (controls or groups).ab.
44. or/17-43
45. 8 and 16 and 44
46. exp animals/ not humans.sh.
47. 45 not 46

Appendix 3. Embase search strategy
1. cerebrovascular disease/ or exp basal ganglion hemorrhage/ or exp brain hemangioma/ or exp brain hematoma/ or exp brain hemorrhage/ or exp brain infarction/ or exp brain ischemia/ or exp carotid artery disease/ or exp cerebral artery disease/ or exp cerebrovascular accident/ or exp cerebrovascular malformation/ or exp intracranial aneurysm/ or exp occlusive cerebrovascular disease/ or exp vertebrobasilar insufficiency/
2. (stroke$ or poststroke or apoplex$ or cerebral vasc$ or brain vasc$ or cerebrovasc$ or cva$ or SAH).tw.
3. ([brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebr$ or mca$ or anterior circulation or basilar artery or vertebral artery] adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
Appendix 4. CINAHL search strategy

S1 ("Cerebrovascular Disorders") OR ("Basal Ganglia Cerebrovascular Disease") OR ("Carotid Artery Diseases") OR ("Cerebral Ischemia") OR ("Cerebral Vasospasm") OR ("Intracranial Arterial Diseases") OR ("Intracranial Embolism and Thrombosis") OR ("Intracranial Hemorrhage") OR ("Stroke") OR ("Vertebral Artery Dissections") OR ("Stroke Patients") OR ("Stroke Units")

S2 T1 ("stroke or poststroke or post-stroke or cerebrovasc" or "brain vasc" or "cerebral vasc or cva or apoplex or SAH") or AB ("stroke or poststroke or post-stroke or cerebrovasc" or "brain vasc" or "cerebral vasc or cva or apoplex or SAH")

S3 T1 ("brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle cerebral artery or MCA or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying") NS ("ischemia" or "ischaemia" or "infarct" or "thrombo" or "emboli" or "occlusion") OR AB ("brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle cerebral artery or MCA or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying") NS ("ischemia" or "ischaemia" or "infarct" or "thrombo" or "emboli" or "occlusion")

S4 T1 ("brain or cerebr* or cerebell* or intracran* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal ganglia* or putaminal or putamen or posterior fossa or hemispher* or subarachnoid") NS ("hemorrhage" or "haemorrhage" or "haematoma" or "hematoma" or "bleed") OR AB ("brain or cerebr* or cerebell* or intracran* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal ganglia* or putaminal or putamen or posterior fossa or hemispher* or subarachnoid") NS ("hemorrhage" or "haemorrhage" or "haematoma" or "hematoma" or "bleed")

S5 T1 ("Hemiplegia") OR ("Gait Disorders, Neurologic")

S6 T1 ("Hemiplegia" or "hemipar* or paresis or paretic") OR AB ("hemipleg*" or "hemipar*" or "paresis or paretic")

Interventions for sexual dysfunction following stroke (Review)
Appendix 5. AMED search strategy

1. cerebrovascular disorders/ or cerebral hemorrhage/ or cerebral infarction/ or cerebral ischemia/ or cerebrovascular accident/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or isch?emi$ attack$ or tia$1 or neurologic$ or deficit$ or SAH or AVM).tw.
3. ((brain$ or cerebr$ or cerebell$ or cortical or vertebrobasilar or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or MCA or anterior circulation or posterior circulation or basal ganglia) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypox$ or vasospasm or obstruction or vasculopathy)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or subarc$ or putaminal or putamen or posterior fossa) adj5 (haemorrhage$ or hemorrhage$ or haematoma$ or bleed$)).tw.
5. hemiplegia/ or gait disorders/ or muscle spasticity/
6. aphasia/
7. (hempar$ or hemiple$ or paresis or paretic or aphas$ or dysphas$ or hemianop$).tw.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7.
9. exp sex/ or exp sex behavior/ or exp sex counseling/ or sex disorders female/ or sex disorders male/ or "sexual and gender disorders"/ or psychosexual disorders/ or exp sexual dysfunctions/
10. ((sexual$ or libido) adj5 (disorder$ or declin$ or dysfunct$ or impair$ or deficit$ or disabilit$ or problem$ or concern$ or difficult$)).tw.
11. (sexual$ adj5 (activ$ or health or issue$ or satisfaction or function$ or experience$ or adjustment or chang$ or knowledge or relation$ or skill$ or intercourse or interest$ or wish$ or need$ or behav$ or perform$ or spouse or partner or wife or husband) ) OR AB ((sexual$ n5 (activ$ or health or issue$ or satisfaction or function$ or experience$ or adjustment or chang$ or knowledge or relation$ or skill$ or intercourse or interest$ or wish$ or need$ or behav$ or perform$ or spouse or partner or wife or husband) )
12. TI ((sexual$ n5 (therap$ or treat$ or rehab$ or train$ or counsel$ or psycholog$ or psychother$ or physiothera$ or help$ or adv$ or inform$ or guid$ or intervention$ or educat$)) ) OR AB ((sexual$ n5 (therap$ or treat$ or rehab$ or train$ or counsel$ or psycholog$ or psychother$ or physiothera$ or help$ or adv$ or inform$ or guid$ or intervention$ or educat$)) )
13. TI (intimata* n3 (relation* or spouse or partner or wife or husband)) OR AB (intimata* n3 (relation* or spouse or partner or wife or husband))
14. TI (marital n3 relation*) OR AB (marital n3 relation*)
15. S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14
16. MH Random Assignment or MH Single-blind Studies or MH Double-blind Studies or MH Triple-blind Studies or MH Crossover design or MH Factorial Design
17. TI ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study") OR AB ("multicentre study" or "multicenter study" or "multi-centre study" or "multi-center study")
18. TI random* or AB random*
19. AB (lating square) or TI (lating square)
20. TI (crossover or cross-over) or AB (crossover or cross-over) or SU (crossover or cross-over)
21. MH Placebos
22. AB (singl* or doubl* or trebl* or tripl*) or TI (singl* or doubl* or trebl* or tripl*)
23. TI blind* or AB mask* or TI mask*
24. S22 and S23
25. TI Placebo* or AB Placebo* or SU Placebo*
26. MH Clinical Trials
27. TI (Clinical AND Trial) or AB (Clinical AND Trial) or SU (Clinical AND Trial)
28. S16 or S17 or S18 or S19 or S20 or S21 or S24 or S25 or S26 or S27
29. S7 AND S15 AND S28

Interventions for sexual dysfunction following stroke (Review)
Appendix 6. PsycINFO search strategy

1. cerebrovascular disorders/ or cerebral hemorrhage/ or exp cerebral ischemia/ or cerebral small vessel disease/ or cerebrovascular accidents/ or subarachnoid hemorrhage/
2. (stroke$ or poststroke or apoplex$ or cerebral vasc$ or brain vasc$ or cerebrovasc$ or cva$ or SAH).tw.
3. ((brain or cerebr$ or cerebell$ or vertebrobasil$ or hemispher$ or intracran$ or intracerebral or infratentorial or supratentorial or middle cerebral artery or MCA$ or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying) adj5 (isch? emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypoxi$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli$ or putaminal or putamen or posterior fossa or hemispher$ or subarachnoid) adj5 (h$emorrhag$ or h$ ematoma$ or bleed$)).tw.
5. hemiparesis/ or hemiplegia/
6. exp aphasia/
7. hemianopia/
8. (hemipa$ or hemipleg$ or paresis or parietic or aphasia* or dysphas$ or hemianop$).tw.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10. psychosexual behavior/ or "erection (penis)"/ or exp human courtship/ or masturbation/ or exp orgasm/ or safe sex/ or exp sexual arousal/ or exp sexual function disturbances/ or exp "sexual intercourse (human)"/ or psychosocial development/ or exp sex/ or sexual attraction/ or sexual fantasy/ or sexual satisfaction/ or sexual partners/
11. ((sexual or libido) adj5 (disorder$ or decline$ or dysfunction$ or impair$ or deficit$ or disabilit$ or problem$ or concern$ or difficult$)).tw.
12. (sexual$ adj5 (activ$ or health or issue$ or satisfaction or function$ or experience$ or adjustment or chang$ or knowledge or relation$ or skill$ or intercourse or interest$ or wish$ or need$ or behavior$ or perform$ or spouse or partner or wife or husband$)).tw.
13. (sexual$ adj5 (therap$ or treat$ or rehab$ or train$ or counsel$ or psycholog$ or psychother$ or physiotherapy$ or help$ or advi$ or inform$ or guid$ or intervention$ or educat$)).tw.
14. (erectile adj3 (function$ or dysfunction$)).tw.
15. (intima$ adj3 (relation$ or spouse or partner or wife or husband$)).tw.
17. 10 or 11 or 12 or 13 or 14 or 15 or 16
18. clinical trials/ or treatment effectiveness evaluation/ or placebo/
19. (random$ or RCT or RCTs).tw.
20. (controlled adj5 (trial$ or study$)).tw.
22. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
23. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
24. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
25. (singl$ or doub$ or tripl$ or trebl$) adj5 (blind$ or mask$).tw.
26. (cross-over or cross over or crossover).tw.
27. (placebo$ or sham).tw.
28. trial.ti.
29. (assign$ or allocat$).tw.
30. controls.tw.
31. or/18-30
32. 9 and 17 and 31

Appendix 7. PEDro search strategy

neurology in the <Subdiscipline> field
clinical trial in the <Method> field
(sexual OR erectile dysfunction OR arousal OR intimacy OR impotence) in the <Title & Abstract> field

Appendix 8. CIRRIE search strategy

Basic search: stroke AND sexual OR stroke AND erectile dysfunction OR stroke AND arousal OR stroke AND intimacy OR stroke AND impotence

Appendix 9. DARE search strategy

Basic search: stroke AND sexual OR stroke AND erectile dysfunction OR stroke AND arousal OR stroke AND intimacy OR stroke AND impotence
Appendix 10. ProQuest search strategy

(ti,ab((sexual* or libido) NEAR/5 (disorder* OR declin* OR dysfunct* OR impair* OR deficit* OR disabilit* OR problem* OR concern* OR difficult*)) OR ti,ab((sexual* NEAR/5 (activ* OR health OR issue* OR satisfaction OR function* OR experience* OR adjustment OR chang* OR knowledge OR relation* OR skill* OR interest* OR wish* OR need* OR behav* OR perform* OR spouse OR partner OR wife OR husband)) OR ti,ab((sexual* NEAR/5 (therap* OR treat* OR rehab* OR train* OR counsel* OR psycholog* OR psychother* OR physiotherapy* OR help* OR advi* OR inform* OR guid* OR intervention* OR educat*)) OR ti,ab((erectile NEAR/3 (function* OR dysfunction*)))) AND ti,ab((stroke or poststroke or "post-stroke" or cerebrovasc* or brain next vasc* or cerebral next vasc* or cva* or apoplex* or SAH))

Appendix 11. OT Search by the American Occupational Foundation and the American Occupational Therapy Association

Basic search: stroke AND sexual OR stroke AND erectile dysfunction OR stroke AND arousal OR stroke AND intimacy OR stroke AND impotence

Appendix 12. OTSeeker search strategy

Basic search: stroke AND sexual OR stroke AND erectile dysfunction OR stroke AND arousal OR stroke AND intimacy OR stroke AND impotence

Appendix 13. National Rehabilitation Information Center REHABDATA Database search strategy

Basic search: stroke AND sexual OR stroke AND erectile dysfunction OR stroke AND arousal OR stroke AND intimacy OR stroke AND impotence

Appendix 14. SPORTDiscuss search strategy

S1 DE "CEREBROVASCULAR disease" OR DE "BRAIN -- Hemorrhage" OR DE "CEREBRAL embolism & thrombosis" OR DE "STROKE" OR DE "BRAIN -- Wounds & injuries" OR DE "BRAIN damage"
S2 DE "CEREBROVASCULAR disease patients"
S3 TI ( stroke* or poststroke or apoplex* or cerebral vasc* or brain vasc* or cerebrovasc* or cva* or SAH ) OR AB ( stroke* or poststroke or apoplex* or cerebral vasc* or brain vasc* or cerebrovasc* or cva* or SAH )
S4 TI ( brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle cerebral artery or MCA* or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying ) OR AB ( brain or cerebr* or cerebell* or vertebrobasil* or hemispher* or intracran* or intracerebral or infratentorial or supratentorial or middle cerebral artery or MCA* or anterior circulation or posterior circulation or basilar artery or vertebral artery or space-occupying )
S5 TI ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or oclus* or hypoxi* ) OR AB ( ischemi* or ischaemi* or infarct* or thrombo* or emboli* or oclus* or hypoxi* )
S6 S4 AND S5
S7 TI ( brain or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli* or putaminal or putamen or posterior fossa or hemispher* or subarachnoid ) OR AB ( brain or cerebr* or cerebell* or intracerebral or intracran* or parenchymal or intraparenchymal or intraventricular or infratentorial or supratentorial or basal gangli* or putaminal or putamen or posterior fossa or hemispher* or subarachnoid )
S8 TI ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* ) OR AB ( haemorrhage* or hemorrhage* or haematoma* or hematoma* or bleed* )
S9 S7 AND S8
S10 DE "HEMIPLEGIA" OR DE "HEMIPLEGICS"
S11 TI ( hemipelg* or hemipar* or paresis or paretic or brain injur* ) OR AB ( hemipelg* or hemipar* or paresis or paretic or brain injur* )
S12 S1 OR S2 OR S3 OR S6 OR S9 OR S10 OR S11
S13 (DE "HUMAN sexuality") OR (DE "SEXUAL exercises") OR (DE "GENITALIA")
S14 TI ((sexual* or libido) n5 (disorder* or declin* or dysfunct* or impair* or deficit* or disabilit* or problem* or concern* or difficult*)) OR AB ((sexual* or libido) n5 (disorder* or declin* or dysfunct* or impair* or deficit* or disabilit* or problem* or concern* or difficult*))
S15 TI ((sexual* or libido) n5 (activ* or health or issue* or satisfaction or function* or experience* or adjustment or chang* or knowledge or relation* or skill* or intercourse or interest* or wish* or need* or behav* or perform* or spouse or partner or wife or husband)) OR AB ((sexual* or libido) n5 (activ* or health or issue* or satisfaction or function* or experience* or adjustment or chang* or knowledge or relation* or skill* or intercourse or interest* or wish* or need* or behav* or perform* or spouse or partner or wife or husband))
S16 TI ((sexual* n5 (therap* or treat* or rehab* or train* or counsel* or psycholog* or psychother* or physiotherapy* or help* or advi* or inform* or guid* or intervention* or educat*)) OR AB ((sexual* n5 (therap* or treat* or rehab* or train* or counsel* or psycholog* or psychother* or physiotherapy* or help* or advi* or inform* or guid* or intervention* or educat*)))
S17 TI ((erectile n3 (function* or dysfunction*))) OR AB ((erectile n3 (function* or dysfunction*)))
S18 TI ((intima* n3 (relation* or spouse or partner or wife or husband)) OR AB ((intima* n3 (relation* or spouse or partner or wife or husband)))
S19 TI (marital n3 relation*) OR AB (marital n3 relation*)
S20 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S19
S21 S12 AND S20

Appendix 15. CT.gov search strategy

( sexual OR erectile dysfunction OR arousal OR intimacy OR impotence ) AND ( Brain Infarction OR Intracranial Hemorrhages OR Carotid Artery Diseases OR Brain Ischemia OR Cerebral Hemorrhage OR Cerebrovascular Disorders OR Stroke ) [DISEASE]

Appendix 16. World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) search strategy

Basic search: stroke AND sexual OR stroke AND erectile dysfunction OR stroke AND arousal OR stroke AND intimacy OR stroke AND impotence

Appendix 17. ISRCTN Registry search strategy

Basic search: stroke AND sexual OR stroke AND erectile dysfunction OR stroke AND arousal OR stroke AND intimacy OR stroke AND impotence

HISTORY

Review first published: Issue 5, 2020

CONTRIBUTIONS OF AUTHORS

Louisa Ng led the review, identified relevant articles, assisted with data extraction, reviewed the papers, provided methodological and content expertise, revised and finalised drafts of the review, and responded to all editorial comments.

Hezekiah Stratton identified relevant articles, assisted with data extraction, reviewed the papers, and wrote the drafts of the review.

Anita Brown-Major, Joshua Sansom, and Paul Anderson provided content expertise and comments on the final drafts of the review.

DECLARATIONS OF INTEREST

Hezekiah Stratton: none known.
Joshua Sansom: author of an included study (Ng 2017).
Anita Brown-Major: none known.
Paul Anderson: none known.
Louisa Ng: author of an included study (Ng 2017).

SOURCES OF SUPPORT

Internal sources
• University of Melbourne, Australia

External sources
• None, Other

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

2019: The secondary outcome measure of 'satisfaction with sexual rehabilitation services' has been changed to 'satisfaction with intervention' for better coverage of all interventions - not just those related to sexual rehabilitation. We have also broadened the secondary outcome of 'marital/relationship satisfaction' to include partner satisfaction.

For future updates, we will separate device interventions and psychological interventions into two categories instead of including them in the same 'non-pharmacological' subgroup of interventions. We will also consider sex-disaggregated analyses.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Stratton, H; Sansom, J; Brown-Major, A; Anderson, P; Ng, L

Title:
Interventions for sexual dysfunction following stroke

Date:
2020

Citation:

Persistent Link:
http://hdl.handle.net/11343/274909